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Objectives: The first part of this study aims to assess the impact of major depressive disorder 
(MDD) on cancer survival and to determine whether the impact is modified by the number of 
other comorbidities in a patient. The second part evaluates the impact of adequate antidepressant 
refill (AAR) on the survival of older cancer patients with MDD. 
Methods: The study used a retrospective cohort design and conducted a population-based study 
on all adult cancer patients diagnosed in Ontario between 2003 and 2013. The cohort was 
followed until 2018. Patients who had a hospital discharge diagnosis of MDD before or during 
the study period were identified as having depression. For the second part of the study, data on a 
subset of patients who were ≥ 65 years old at the time of cancer diagnosis and had MDD were 
analysed. Fifteen chronic conditions were included for calculating the number of comorbidities 
excluding MDD. Survival analysis was performed using Cox proportional hazards regression. 
Results: Among the 453,012 adults diagnosed with cancer, 2% had a hospital diagnosis of 
MDD. Those who had MDD had a higher risk of mortality (adjusted hazard ratio (aHR) 1.58; 
95% confidence interval (CI) 1.54-1.63) than those without MDD. In patients with MDD, those 
with 0-1 comorbidities had 2.55 times (aHR 2.55; 95% CI 2.31-2.81), those with 2-3 
comorbidities had 1.85 times (aHR 1.85; 95% CI 1.75-1.95), and those with ≥ 4 comorbidities 
had 1.44 times (aHR 1.44; 95% CI 1.40-1.49) higher risk of death compared to patients without 
MDD with similar levels of multimorbidity. There were 4,708 patients who were ≥ 65 years old 
and had MDD. Among patients whose MDD was diagnosed after cancer (N=3,183 (67.6%)), 
AAR was associated with a lower mortality risk (aHR 0.51; 95% CI 0.47-0.55).  
Conclusion: Cancer patients without MDD survive longer than those with MDD. Older patients 
with MDD diagnosed after cancer are likely to survive longer if they receive AAR. 
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Overview of Thesis Content  
This thesis is organized into seven chapters. The first chapter provides a general 
introduction of the topics of this research; depression, multimorbidity, and cancer survival. The 
second chapter is a literature review synthesizing what is known about the study topics. The third 
chapter provides a thesis overview which outlines the study objectives and hypotheses, approach 
to the thesis, and ethical considerations. Chapters 4 and 5 are the publishable manuscripts. 
Chapter 4 addresses the first two objectives, i.e., determining whether MDD has an impact on the 
survival of cancer patients and whether number of other comorbidities modifies this impact. 
Chapter 5 addresses the third objective, i.e., evaluating whether adequate antidepressant refill has 
an impact on the survival of cancer patients with MDD. The sixth chapter is a general discussion 
of the overall findings of the study, their epidemiological implications, and the strengths and 
limitations of the study. Chapter 7, conclusions, is the final chapter and summarizes the study 
findings and their implications and suggests directions for future research. 
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Impacts of Depression and its Management on the Survival of Cancer Patients With and 
Without Other Chronic Diseases 
Cancer is ranked first among the leading causes of death in Canada (Statistics Canada, 
2018a). Almost one in two Canadians will have cancer in their lifetime and it will be the cause of 
death for one in four Canadians (Canadian Cancer Society, 2019). These statistics are similar for 
the province of Ontario where there were more than 90,000 newly diagnosed cases of cancer and 
30,000 deaths due to cancer in 2018 (Cancer Care Ontario, 2018). It is estimated that the five-
year survival rate for all cancers combined for Canadians is 60% (Canadian Cancer Society, 
2019).  
The risk for cancer increases with age, with nearly 90% of patients receiving a cancer 
diagnosis after 50 years of age (Canadian Cancer Society, 2019). Because older age is associated 
with increased prevalence of chronic diseases, patients with cancer are also likely to have other 
chronic diseases. Modifiable risk factors for many cancers are also risk factors for other chronic 
diseases, including tobacco, alcohol, overweight/obesity, poor-quality diet, and inadequate 
physical activity (World Health Organization, n.d.). Cancer patients are more likely to have co-
existing medical conditions (i.e., comorbidities) than people with no diagnosis of cancer (Ng et 
al., 2018).  
Symptoms of comorbid conditions can mask the symptoms of cancer and cause delay in 
cancer diagnosis, which can negatively affect survival (O’Rourke et al., 2008). However, it has 
also been suggested that comorbidities may be associated with frequent health system 
encounters, which can lead to earlier detection of cancer (Iachina et al., 2014). Comorbidities can 
predispose cancer patients to poorer outcomes such as surgical complications, increased length 
of hospital stay, and increased mortality (Chaudhary et al., 2013; Dehal et al., 2013; Dolan et al., 
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2013; Genther & Gourin, 2015). The severity of comorbidities such as heart disease and chronic 
obstructive pulmonary disease (COPD) can decrease the survival of cancer patients (Iachina et 
al., 2014). Many chronic conditions including hypertension, heart disease, diabetes, and high 
cholesterol are common in cancer patients (Sarfati et al., 2016). Depression, with a prevalence of 
6.8%, is the most common psychiatric condition among advanced cancer patients (Kadan-Lottick 
et al., 2005). 
Depression affects cancer patients more than the general population (Hong & Tian, 
2014a; Watts et al., 2015). Chronic diseases and cancer can both increase the risk of developing 
depression, as depression can be triggered by situations causing feelings of hopelessness and 
helplessness (Halberstadt et al., 1984). Among cancer patients, those who have had a past history 
of depression or who were undergoing treatment for depression had increased depression scores 
over a two-year follow-up period than those with no history of depression (Stafford et al., 2016). 
Even cancer survivors who have been cancer-free for five years or more have high levels of 
depression (Muzzatti et al., 2017). Depression can make cancer care challenging due to poor 
treatment adherence (Hooper et al., 2016; Moraes & Casseb, 2017) and engagement in unhealthy 
behaviours (Barros et al., 2017). Depression is associated with poor quality of life (K. H. Hwang, 
Cho, & Yoo, 2016; Shakeri et al., 2016) and poor prognosis/outcomes such as mortality in 
cancer patients (Kanani et al., 2016; Low et al., 2016). However, proper screening for, and 
treatment of depression is cost effective and increases quality-adjusted life years in cancer 
patients (Duarte et al., 2015; S. Walker et al., 2014).  
Although Canada has universal health care funded through the income tax system 
(Ontario, 2020a) that pays for basic health care for all residents, Canadians’ mental health needs, 
such as need for information regarding mental health conditions and treatments/services, 
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medication, counselling, and other mental health services are frequently not met (Sunderland & 
Findlay, 2013). Many parts of Canada have shortages of mental health providers (Anderssen, 
2020). In 2012, 12.2% Canadians had unmet mental health needs and 21.1% had partially met 
mental health care needs (Sunderland & Findlay, 2013). Those who had one or more chronic 
physical conditions were more likely to have mental health care needs than those who did not 
have any chronic diseases; however, those who had chronic physical diseases were likely to have 
their mental health needs taken care of by receiving information, medication, counselling, or 
other mental health services (Sunderland & Findlay, 2013). Only 50% of Canadians with a major 
depressive episode received adequate treatment (received antidepressants or visited a health care 
provider at least six times a year for mental health reasons) in 2012 (Patten et al., 2016). 
The high prevalence of depression and other comorbidities in cancer patients and the 
mixed evidence about the impact on depression on cancer survival leads to the question how 
depression and its management influence cancer survival among Canadians, especially given the 
shortcomings of the Canadian health system in providing mental health care. Even though there 
have been studies examining the effect of depression and comorbidities separately on the 
survival of cancer patients, what remains unknown is the combined effect of depression and 
other comorbidities on cancer survival. This study examines whether depression has an impact 
on the survival of cancer patients in Ontario and whether this effect is modified by the presence 
of other comorbidities. The study will also assess whether Ontario Health Insurance Plan 
(OHIP)-covered treatment for depression (i.e., pharmacotherapy) has an impact on the survival 
of cancer patients with depression. 
  














Chapter 2: Literature Review 
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This study aims to evaluate the impact of depression on cancer survival in the context of 
multimorbidity (co-occurrence of more than one chronic disease in a person) and determine 
whether adequate antidepressant use has an impact on the survival of cancer patients with 
depression. The existing literature was searched for studies of outcomes in cancer patients, 
especially in the context of multimorbidity and depression. Reports and peer-reviewed 
publications that examined the prevalence of multimorbidity and depression, and their impact on 
the quality of life and survival in cancer patients, were included in the review. Search was 
conducted in PubMed using combinations of the following keywords: comorbid*, 
"Comorbidity"[Mesh], "Multimorbidity"[Mesh], surviv*, "Mortality"[Mesh], "Survival"[Mesh], 
depress*, “Depressive Disorder"[Mesh], "Depression"[Mesh], malignan*, cancer*, 
"Neoplasms"[Mesh], and antidepressant*.  In what follows, I present the results of the literature 
review to provide a brief background on the topics of this study. It is divided into the following 
sections: cancer, multimorbidity in cancer patients, depression in cancer patients, possible 
mechanisms by which depression and other comorbidities affect cancer survival, and 
antidepressant therapy in cancer patients. 
2.1 Cancer 
Cancer results from uncontrolled division of abnormal cells which can also invade and 
spread to other parts of the body (National Cancer Institute, n.d.). Internationally, around 17 
million new cases of cancer were diagnosed in 2018 (Cancer Research UK, n.d.). In Canada, 
there were 206,200 newly diagnosed cancer patients in 2017 (Canadian Cancer Society, 2017). 
In 2009, 2.4% of Canadians who were alive have had a diagnosis of cancer in the preceding 10 
years (Canadian Cancer Society, 2017). Cancer was the main cause of premature mortality in 
Canada, as the years of potential life lost was the highest for cancer than all other causes of 
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premature death (Canadian Cancer Society, 2017). Among all health conditions, cancer had the 
highest cost of productivity loss due to premature death in Canada in 2010 (The Public Health 
Agency of Canada., 2017). Health care costs in Canada associated with cancer was $7.5 billion 
in 2012 (de Oliveira et al., 2018).  
The most common cancers in Canada are breast, lung and bronchus, prostate, colorectal, 
and bladder cancers, which account for more than 50% of the newly diagnosed cancers 
(Statistics Canada, 2019). Half of the deaths due to cancer in Ontario are attributable to lung, 
colorectal, female breast, and pancreatic cancers, with lung cancer accounting for almost one-
fourth of all cancer deaths (Cancer Care Ontario, 2018).  However, improved treatment and 
routine screening have resulted in improved survival rates for breast, prostate, and colorectal 
cancers (Cancer Care Ontario, 2016). 
2.1.1 Cancer Survival 
Multiple clinical and sociodemographic factors can impact cancer survival. Patient 
survival rates vary by cancer type. For example, the five-year survival rate for lung cancer is 
only 17% while it is 95% for prostate cancer (Canadian Cancer Statistics Advisory Committee, 
2018). Diagnosing cancer at its earlier stages can result in better survival rates (Canadian Cancer 
Statistics Advisory Committee, 2018). Non-small cell lung cancer, which is the most common 
type of lung cancer in Canada, has a five-year survival rate of 60% if diagnosed in the localized 
stage, whereas if diagnosed after spreading to distant organs, the five-year survival rate is as low 
as 6% (American Cancer Society, 2019a). Five-year survival rates for breast cancer and cancers 
of colon and rectum are around 99% and 90% respectively, if diagnosed at localized stage, and 
27% and 15% respectively, if diagnosed after distant spread (American Cancer Society, 2019b, 
2019c).  
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Other factors that influence cancer survival are demographics and socioeconomic status. 
Increasing age is a factor associated with poorer cancer survival (Sugiura et al., 2017; S. F. 
Wong et al., 2016), although the relationship can change according to the type of cancer. For 
example, breast cancer patients diagnosed before age 35 (Wei et al., 2013) and prostate cancer 
patients diagnosed between ages 40 and 44 (Merrill & Bird, 2002) were found to have poorer 
survival than those who were diagnosed at later ages. Males are reported to have generally 
poorer cancer survival rates than females  (Ellison, 2016; Kinoshita et al., 2017; Radkiewicz et 
al., 2017). This can be due to various factors such as women giving more attention to their 
bodies, leading to earlier diagnosis and better treatment; biological and hormonal factors that 
favour survival in women; men having more exposure to cancer risk factors; and the differences 
in the distribution of cancer sub-sites among men and women (Micheli et al., 1998). Women are 
also higher users of health care services (Bertakis et al., 2000), which can also favor their 
survival. Ethnicity also contributes to cancer survival. Asian ethnicity has been found to be 
associated with better survival than non-Asian ethnicity among cancer patients, likely due to 
differences in tumor biology, lower smoking prevalence, and higher likelihood of being married 
or having a partner (J. D. Kim et al., 2017). Immigrants in Canada have lower mortality due to 
cancer when compared to individuals born in Canada (Cheung et al., 2017). 
First Nation adults have lower survival than non-Indigenous Canadians (Withrow et al., 
2017), likely due to stage at diagnosis, health behaviours, prevalence of comorbidities, and 
disparities in screening uptakes (Withrow et al., 2017). Indigenous people living in First Nation 
communities may have limited access to care (Lavoie et al., 2016). Racial stereotyping can lead 
to Indigenous patients’ health complaints being trivialized and receiving poor quality of care 
(Browne & Fiske, 2001), which can also impact their disease prognosis. A study in New Zealand 
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showed that Indigenous cancer patients are less likely to undergo definitive treatment and are 
likely to have delay in time between diagnosis and treatment (Hill et al., 2010).  
Income predicts survival probability in cancer patients and higher income is associated 
with better survival (Altman et al., 2017; Choi et al., 2016; Singer et al., 2017). Low income 
might limit access to healthy food which can lead to undernutrition, which in turn can result in 
low immunity and poor survival (Kau et al., 2011). Low-income patients are likely to forgo care 
(T. J. Kim et al., 2017), which can also negatively impact cancer survival. In Canada, access to 
care individuals with higher income had better access to care than those with lower income 
(Lasser et al., 2006). Patients living in areas which fall under lower income quintiles in Canada 
have poorer cancer survival than those living in areas with higher income (C. Boyd et al., 1999; 
McDonald et al., 2014).  
Rurality of residence can be associated with increased travel for accessing health care, 
which can impact the quality of care and treatment adherence of cancer patients resulting in 
poorer survival. However, there are studies that have shown an advantage in survival among 
cancer patients who are living in urban areas when compared to those living in rural areas 
(Zhang et al., 2015), although there are many studies showing that there is no such impact 
(Canale et al., 2018; J. D. Kim et al., 2018). In Canada, neighbourhoods that are most 
socioeconomically deprived are also generally situated far from treatment centres, which means 
that poor people have to travel further to get cancer treatment (B. B. Walker et al., 2017), which 
is likely to impact their care-seeking behaviour and survival. 
2.2 Multimorbidity in Cancer Patients 
Multimorbidity is the presence of multiple chronic diseases in the same patient. There are 
multiple methods of measuring multimorbidity in patients such as Elixhauser Comorbidity Index, 
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which considers duration of hospital stay hospital costs and mortality and is commonly used in 
hospitalized patients (Elixhauser et al., 1998),  Charlson Comorbidity Index, which is commonly 
used in cancer patients and uses administrative databases for classifying multimorbidity 
according to number and severity of diseases, (Charlson et al., 1987); Comorbidity-
Polypharmacy Score, which is commonly used in trauma patients and considers number of 
medications as well as comorbidities (Evans et al., 2011); and number of different diagnoses (Lix 
et al., 2011).  
It has been estimated that 26% of Canadians aged 40 years or more had two or more 
chronic conditions in 2011/2012 (Feely et al., 2017). Among cancer patients in Ontario, the 
prevalence of multimorbidity was estimated to be more than 70% in 2009 (Koné Pefoyo et al., 
2015). Prevalence of multimorbidity varies according to the type of cancer. For example, one 
study showed that while the prevalence of at least one comorbidity in lung cancer patients was 
53%, it was only 30.5% in prostate cancer patients (Edwards et al., 2014). Among cancer 
patients who are 65 years or older, the prevalence of comorbidities can be as high as 90% 
(Williams et al., 2018). Further, the diagnosis of cancer could lead to the diagnosis of other 
conditions because frequent encounters with the health care system following cancer diagnosis 
can facilitate the detection of previously undiagnosed conditions.  
Sociodemographic factors including sex, ethnicity, and income influence multimorbidity 
(Agborsangaya et al., 2012). Females have increased risk of multimorbidity compared to males 
in all age groups (Agborsangaya et al., 2012). Contributing factors could include greater 
susceptibility of females to some conditions such as autoimmune diseases (Hayter & Cook, 
2012). In general, females live longer than males, which also makes them more likely to have 
multiple chronic diseases. When compared to Whites, Asians have lower risk for multimorbidity 
IMPACTS OF DEPRESSION AND ITS MANAGEMENT ON CANCER SURVIVAL 
11 
 
while Blacks have a higher risk (St Sauver et al., 2015). Risk of multimorbidity is inversely 
related to income (Agborsangaya et al., 2012).  
2.2.1 Multimorbidity and Cancer Survival 
Multimorbidity is associated with increased mortality in cancer, regardless of the type of 
cancer (Parés-Badell et al., 2017; Patel et al., 2017; Phillips et al., 2017). Among the studies on 
multimorbidity and survival in cancer patients, some have included only specific cancers 
(Phillips et al., 2017; Patel et al., 2017) whereas others have included all types of cancers (Lee et 
al., 2017). High degree of multimorbidity has been found to be associated with higher risk for 
death in epithelial ovarian cancer (Phillips et al., 2017), metastatic renal cell carcinoma (Patel et 
al., 2017), and breast, lung and colorectal cancers (Parés-Badell et al., 2017). Higher values in 
comorbidity scores such as Charlson comorbidity index and Cumulative Illness Rating Scale-
Geriatric, calculated by taking into account the comorbidities and their severity in a patient, have 
a negative impact on cancer survival (Lee et al., 2017; Matthes et al., 2018; Phillips et al., 2017).  
Multiple health care professionals are involved in taking care of each cancer patient, potentially 
including physicians, nurses, pharmacists, dieticians, psychologists, etc. (Canadian Cancer 
Society, n.d.). Physicians who specialize in specific areas such as medical oncologists, radiation 
oncologists, surgical oncologists, pathologists, anaesthesiologists, and the family physician take 
part in providing care to cancer patients as required (Canadian Cancer Society, n.d.). If a cancer 
patient has other chronic conditions, which also require ongoing management, they need services 
from multiple physicians and other health care professionals. For example, a patient with cancer 
and rheumatoid arthritis needs an oncologist and a rheumatologist work closely for optimization 
of care since the medicines for rheumatoid arthritis can cause immunosuppression (Zogala et al., 
2017). Cancer patients with diabetes require individualized care by a multidisciplinary team 
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consisting of oncologists and diabetes specialists (Jacob & Chowdhury, 2015). When multiple 
disciplines/specialities are involved in a patient’s care, care coordination can be challenging, 
especially when the providers are located in different communities as can be the case for rural 
patients. Hence, cancer care can be complicated by multimorbidity. 
2.2.2 Common Comorbidities in Cancer 
Frequently reported comorbidities in cancer patients include hypertension, coronary heart 
disease, myocardial infarction, stroke, COPD, peptic ulcer, diabetes, renal insufficiency, liver 
insufficiency, and arthritis (Edwards et al., 2014; C. Ko & Chaudhry, 2002). Multimorbidity is 
particularly associated with higher risk for depression. When compared to people with no 
chronic physical conditions, having a chronic physical condition increases the risk for depression 
by two times and having two or more chronic physical conditions increases the risk by three 
times (Read et al., 2017). 
2.3 Depression in Cancer Patients 
Depression is a common mental health condition in which the affected person loses 
interest in activities previously enjoyed and experiences sadness and worthlessness for longer 
periods of time than what is expected in grieving (American Psychiatric Association, 2013). The 
annual prevalence of major depression in Canada is around 5% (Patten et al., 2016). Cancer 
patients have higher prevalence of depression than the rest of the population (Mols et al., 2018). 
A systematic review by Walker et al. (2013) found that the prevalence of depression ranged from 
5% to 16% in cancer patients receiving outpatient care whereas it was as high as 7% to 49% in 
cancer patients receiving palliative treatment.  
Although females are more likely to have depression than males (Knoll & MacLennan, 
2017), it may not always be the case for cancer patients. For example, among colorectal cancer 
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patients, one study showed that males have higher odds for depression than females (Mols et al., 
2018) while another study showed higher odds in females (Clark et al., 2016). Among lung 
cancer patients, females were found to be more likely to have depression than males (Hung et al., 
2017). Another factor that contributes to depression in cancer patients is age, although the pattern 
may change according to cancer type. Among colorectal patients, older age was found to be 
associated with higher odds of depression (Mols et al., 2018), whereas among breast cancer 
(Cvetković & Nenadović, 2016) and lung cancer (Hung et al., 2017) patients, younger age was 
associated with higher odds of severe depression. Lower socioeconomic status, non-White 
ethnicity (Clark et al., 2016), and immigrant status (Butow et al., 2013) are also associated with 
higher likelihood for depression among cancer patients. Stage of cancer and presence of 
comorbidities also contribute to depression in cancer patients (Clark et al., 2016). 
Physical symptoms such as pain (Hong & Tian, 2014) and impairment in activities of 
daily living (Clark et al., 2016; Hong & Tian, 2014) can increase the risk of depression among 
cancer patients. At the same time, not everyone who receives a cancer diagnosis becomes 
depressed. One can experience stress associated with the diagnosis and treatment of cancer; 
however, symptoms of depression are likely to improve with time following cancer diagnosis 
(Mols et al., 2018).  
2.3.1 Depression and Cancer Survival 
There is mixed evidence about the effect of depression on cancer patients’ survival, with 
some studies showing evidence that cancer patients with depression had lower survival than 
those without depression (Chang et al., 2014; Goodwin et al., 2004; Prasad et al., 2014; Prieto et 
al., 2005; Shinn et al., 2016) and some studies showing no such effect (Faller & Schmidt, 2004; 
Nakaya et al., 2006). One study that evaluated the impact of depression or anxiety on survival 
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showed that among cancer patients, those with anxiety and/or depression had 83% (HR 1.83; 
95% CI 1.45-2.31) higher risk for death than those without anxiety and/or depression, although 
those who contacted a mental health professional in the past year had no excess mortality related 
to anxiety or depression (Pratt et al., 2016). Another study that examined whether past history of 
a hospitalization due to severe mental illnesses and comorbidities had an effect on the survival of 
newly-diagnosed cancer patients showed that cancer patients with history of substance abuse 
disorder, psychosis, and mood disorders had higher 5-year cancer-specific mortality rates than 
those without severe mental illnesses (Manderbacka et al., 2017). Studies have failed to find a 
relationship between distress and survival in certain types of cancers such as ovarian cancer and 
advanced lung cancer, both of which typically have poor prognosis (de Mol et al., 2017; 
Minlikeeva et al., 2017). Some studies showed depression was associated with poorer survival at 
shorter periods of observation, but had no effect on longer term or overall survival (Pirl et al., 
2008; Prieto et al., 2005). Pirl et al. (2008) followed 43 patients who were newly diagnosed with 
non-small cell lung cancer and found that depression was associated with higher risk of mortality 
at 6 months although overall mortality was not influenced by depression. The maximum survival 
for the study was 30 months. Prieto et al. (2005) followed 119 hematologic cancer patients and 
found that mortality at 1 and 3 years was influenced by MDD, whereas 5-year mortality was not 
impacted by MDD. However, reverse causality cannot be ruled out in short-term survival in 
cancer patients because patients are likely to develop depression when they know that they have 
a poor prognosis. Time of depression diagnosis may also influence the impact of depression on 
cancer survival, as evidenced by studies that showed that diagnosis of depression years before 
cancer diagnosis was associated with decreased survival (Yang et al., 2018) whereas baseline 
depression present at the time of diagnosis of cancer failed to show any such effect (Liang et al., 
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2017). Several meta-analyses have also shown that depression is associated with decreased 
cancer survival (Pinquart & Duberstein, 2010; Satin et al., 2009; Wang et al., 2019) 
If depression is unrecognized and untreated, it can lead to poorer outcomes in cancer 
patients (Kissane, 2014). Decreases in depression scores have been found to be associated with 
improved survival in cancer patients by one study (Giese-Davis et al., 2011), although a recent 
study by Mulick et al. (2019) did not find any such association. 
2.4 Possible Mechanisms by Which Depression and Other Comorbidities Affect Cancer 
Survival 
There are multiple pathways by which multimorbidity and depression can impact cancer 
survival including delayed cancer diagnosis, nonadherence to treatment and healthy lifestyle, 
poor quality of life, polypharmacy and related drug interactions, severity of comorbid conditions, 
and other health care-related factors.  
2.4.1 Delayed Diagnosis of Cancer 
There are contrasting findings and views about the effect of comorbidities on timely 
diagnosis of cancer. Although it is likely that patients with chronic diseases have more physician 
encounters than those without any chronic diseases, which can lead to early diagnosis of cancer, 
studies have shown that diagnosis of cancer is delayed in patients with comorbidities when 
compared to patients without comorbidities (Mounce et al., 2017; Whitley et al., 2017; Xiao et 
al., 2016). One reason may be that since the health care providers are engaged in caring for the 
already diagnosed conditions in a patient, they fail to recognize the symptoms of cancer and the 
need for cancer screening. The other reason may be that similarities between the symptoms of 
cancer and other co-existing conditions in the same patient might prevent early diagnosis of 
cancer. For example, it has been found that depression is associated with delayed diagnosis of 
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oesophageal cancer (O’Rourke et al., 2008) because dysphagia, which is a common symptom in 
oesophageal cancer, is also common in patients with psychiatric illnesses including depression 
(Regan et al., 2006). 
Depression is associated with decreased self-efficacy (Sympa et al., 2018). Hence 
depressed patients may not undergo screening for cancer and follow treatment recommendations. 
Depending on symptom severity, depressed patients may not be motivated to seek care for any 
condition. A study of US military veterans found that depression and trauma-related symptoms 
were associated with lower likelihood for undergoing prostate cancer screening (Silberbogen et 
al., 2014).   
2.4.2 Adherence to Treatment and Healthy Lifestyle 
Depression is a known risk factor for poor adherence to treatment (Hooper et al., 2016; 
Moraes & Casseb, 2017). Depressed men were found to be less likely to undergo definitive 
therapy such as surgery and radiation for prostate cancer and had lower survival than 
nondepressed men (Prasad et al., 2014). 
Depression has been identified as one of the factors that can prevent cancer survivors 
from adhering to physical activity goals (Black et al., 2018; Chipperfield et al., 2013). 
Depression is associated with higher risk of smoking, recreational drug use (Ruggles et al., 
2017), excessive alcohol use, and unhealthy diet (Barros et al., 2017). Sleep disorders are also 
very common in depressed patients (Nutt et al., 2008), which can also impact quality of life and 
survival of cancer patients with depression. 
Multimorbidity has been found to be associated with premature discontinuation of 
treatment by breast cancer patients (Nabieva et al., 2018). Cancer diagnosis has been found to 
lead to decreased adherence to the comorbidity medications (Banegas et al., 2018), which can 
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result in worsening of comorbid conditions resulting in poorer survival. A study in China found 
that multimorbidity is associated with poorer adherence to cardiovascular medications (M. C. S. 
Wong et al., 2014). 
2.4.3 Quality of Life  
Depression and comorbidities are associated with higher likelihood of fatigue in cancer 
survivors (Hwang I. C. et al., 2014; J. M. Jones et al., 2016; Storey et al., 2012), which can also 
be a barrier for adapting healthier lifestyles (Breedveld-Peters et al., 2018). Colorectal cancer 
patients with depression had higher rates of increase in fatigue and pain and decrease in physical, 
emotional, cognitive, and social functioning after five years following surgery than patients 
without depression (Cummings et al., 2018; Mols et al., 2018). Cancer-related fatigue can persist 
many years after treatment and is associated with increased disability (J. M. Jones et al., 2016). 
Long-term persistence of fatigue in breast cancer patients has been linked to pre-existing 
depression (Schmidt et al., 2015). Fatigue can prevent cancer patients from being physically 
active and hence lead to poorer survival. Depression is also associated with poor health related 
quality of life (HRQoL) even after many years following cancer treatment (Kenzik et al., 2015; 
Schoormans et al., 2015) and poor HRQoL is associated with shorter survival (Kenzik et al., 
2015).  
2.4.4 Polypharmacy 
Multimorbidity frequently requires polypharmacy, which can result in drug interactions 
in cancer patients which can also impact their survival. One study showed that around 58% of 
cancer patients had at least one potential drug interaction (van Leeuwen et al., 2011). A study 
conducted among cancer patients undergoing only palliative treatment showed the prevalence of 
drug interactions to be 31%, of which 59% was of moderate severity (Riechelmann et al., 2008). 
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Among older cancer patients, studies have shown varying prevalence of severe drug interactions 
ranging from 35% (Alkan et al., 2017) to more than 60% (Nightingale et al., 2018).  
2.4.5 Severity of Comorbidities 
Cancer patients with multimorbidity are at risk for death due to cancer as well as risk of death 
from other chronic diseases depending on the severity of the conditions. If cancer is diagnosed at 
an earlier stage (i.e., local or regional stages), they are likely to die due to diseases other than 
cancer, especially in cancers with good prognosis (Edwards et al., 2014). If cancer is diagnosed 
at a later stage (i.e., distant stage) their cause of death is likely to be cancer. Increased 
comorbidity scores are related to higher risk for noncancer-related deaths among cancer patients, 
especially in those diagnosed at an earlier stage (Edwards et al., 2014). Cancer patients with 
depression are four times more likely to have suicidal ideations than those without depression 
(Tang et al., 2016). 
2.4.6 Health Care Factors 
A study done in the United States of America by Druss et al. (2008) found that patients 
with untreated depression are less likely to have a usual source of health care than persons 
without depression. Untreated depression patients are less likely to have had a health care visit in 
a two-year period or receive preventive health services including influenza vaccine, blood 
pressure check, and screening for breast, cervical and colorectal cancers than non-depressed 
individuals (Druss et al., 2008). Failure to receive preventive health services can lead to delayed 
diagnosis of diseases and thus impact survival of depressed patients. Patients who were treated 
for depression in speciality care had a high likelihood of reporting that their primary care 
physician did not inquire about their medications that were prescribed by other providers (Druss 
et al., 2008). Physical complaints of patients with mental illnesses may not be taken seriously or 
IMPACTS OF DEPRESSION AND ITS MANAGEMENT ON CANCER SURVIVAL 
19 
 
attributed to their mental illness (Hamilton et al., 2016; S. Jones et al., 2008). As a result, they 
may not receive timely and appropriate treatment for their physical comorbidities (Atzema et al., 
2011), which can impact their survival. 
 Multimorbid patients receive care from multiple sources including primary care 
physicians, specialists, rehabilitation facilities, inpatient and outpatient hospital settings, and 
counselling services, which are separate entities and the services provided by them are specific 
for particular conditions. The siloed health care systems can make it difficult for patients to 
transition among the care providers (C. M. Boyd & Fortin, 2010). Time constraints of health care 
providers, delay in updating medications and discharge summaries, and unclear medical records 
can adversely affect the quality of care received by patients when multiple specialities and 
providers are involved in their care (Mc Namara et al., 2017), impacting survival. 
2.5 Antidepressant Therapy in Cancer Patients 
Antidepressants are recommended as the first line of treatment for moderate to severe 
depression in cancer patients (Li et al., 2016). In oncology, antidepressants are used for treating 
multiple symptoms in addition to depression (Grassi et al., 2018). It is used for the management 
of pain, hot flashes, nausea/vomiting, poor appetite, and fatigue in cancer patients (Grassi et al., 
2018). Selective serotonin reuptake inhibitors (SSRIs) are considered to the best type of 
antidepressants for treating depression in cancer patients (Grassi et al., 2018). Other 
antidepressant categories used in cancer patients include tricyclic antidepressants, monoamine 
oxidase inhibitors, serotonin antagonist and reuptake inhibitors, selective norepinephrine 
reuptake inhibitors, and serotonin norepinephrine reuptake inhibitors (Grassi et al., 2018). 
On average, it takes one to two weeks of treatment before the patient starts feeling the 
benefits of antidepressant use (American Psychiatric Association, 2010; National Health Service, 
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2018) and it may take four to eight weeks to attain the full benefits of a specific dose (American 
Psychiatric Association, 2010). It is recommended that patient remains on the antidepressant for 
at least six months following symptom remission (National Health Service, 2018). Most of the 
newer-generation antidepressants have some adverse effects associated with their usage 
(Carvalho et al., 2016). They include gastrointestinal symptoms such as nausea and diarrhoea, 
liver toxicity, cardiovascular symptoms, suicidality, hyponatraemia, sexual dysfunction, 
osteoporosis, and hyperprolactinaemia (Carvalho et al., 2016). Hence, antidepressants are 
prescribed to cancer patients only when the benefits outweigh the risks (Li et al., 2016). Certain 
types of antidepressant medications, such as SSRIs, can lead to worsening of some types of 
cancers (see below). 
Demographic factors associated with antidepressant use include age, sex and ethnicity 
(Fisch et al., 2015). Being female, non-Hispanic White ethnicity, and older age are associated 
with higher likelihood for antidepressant usage among cancer patients (Fisch et al., 2015). 
Cancer patients with comorbidities are more likely to use antidepressants within six months 
before and after cancer diagnosis than those without comorbidities (Pearson et al., 2015). Cancer 
patients who are nearing death are also likely to initiate antidepressant therapy (Pearson et al., 
2015). 
2.5.1 Antidepressant Use and Cancer Survival 
Antidepressant use may improve the quality of life of cancer patients with depression 
(Fisch et al., 2003; Nikbakhsh et al., 2018; Pezzella et al., 2001) and as a result improve their 
lifestyle and survival. However, one study showed that antidepressant use did not have an effect 
on the quality of life of cancer patients although the study did not consider the duration of 
antidepressant use (Vyas et al., 2017). There is some evidence that antidepressant use is 
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associated with longer survival in lung cancer patients as shown by one study (Zingone et al., 
2017), although another study among lung cancer patients showed that antidepressant use, 
mental health visits, and hospitalizations for depression were associated with higher risk for 
death (Sullivan et al., 2014). 
Treatment of depression using SSRIs was found to be associated with a higher mortality 
rate in breast cancer patients by one study (Busby et al., 2018) and the investigators suggested 
that it might be because SSRIs increased prolactin levels (Cowen & Sargent, 1997) which 
facilitates progression of breast cancer and metastasis (Tworoger & Hankinson, 2008) or because 
SSRIs reduces the metabolism of tamoxifen (Desmarais & Looper, 2009). A study on ovarian 
cancer patients also showed that SSRI use is associated with faster disease progression 
(Christensen et al., 2016). It is likely that if patients diagnosed with breast or ovarian cancer are 
later diagnosed with depression, they may not receive an antidepressant due to the above facts.  
Past studies have examined the impact of depression and multimorbidity on the survival 
of cancer patients. There was one study that examined the impact of pre-existing mental health 
disorders on survival and found that the impact varied according to number of comorbidities (Lin 
et al., 2016). The study included only lung cancer patients who were beneficiaries of the US 
Military Health System (Lin et al., 2016). There is a paucity of studies at the population level in 
Canada that looked at the combined effect of depression and presence of other comorbidities on 
cancer survival. The conflicting results about the relationship between antidepressants and 
survival in cancer patients and the scarcity of evidence at the population level, especially in 
Canada, call for more research studying the impact of antidepressant therapy on the survival of 
cancer patients with depression. The current study tries to address those gaps in research by 
assessing the impact of depression on the survival of cancer patients in the context of 
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multimorbidity and the impact of antidepressant therapy on the survival of cancer patients with 
depression in Ontario.  
 
  













Chapter 3: Thesis overview 
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 A review of the literature suggests that depression can have a negative impact on cancer 
survival, although it is not known how multimorbidity influences the relationship between 
depression and cancer survival. Also, there is inadequate evidence regarding the impact of 
antidepressant therapy on the survival of cancer patients with depression. This study aims to 
address those gaps in research. Understanding the effect of depression on survival can help 
physicians in decision making regarding management of cancer patients, especially patients with 
multimorbidity who have complex health care needs. Evidence about the impact of adequate 
antidepressant use on cancer survival can assist physicians in managing cancer patients with 
depression efficiently for achieving better outcomes. 
3.1 Objectives 
The aim of this study is to examine whether the presence of depression and other 
comorbidities is associated with survival among cancer patients, and whether adequate 
antidepressant use, defined as taking an antidepressant for 180 days or more (Duhoux et al., 
2012), improves survival among cancer patients with depression. The specific research questions 
that I will investigate are: 
1. Does depression influence the survival of cancer patients in Ontario? 
2. Does the impact of depression on the survival of cancer patients vary according to the 
presence of other comorbidities? 
3. Does adequate antidepressant use affect the survival of cancer patients with depression 
with or without other comorbidities? 
3.2 Approach to Thesis 
A quantitative approach was applied using existing health care administrative data to 
address the research questions. 
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The conceptual framework for this study was based on the Andersen’s Behavioural 
Model of Health Services Use (Andersen, 1995). The model was selected because it explains 
health outcomes as a function of health care utilization; health care needs; and socioeconomic, 
demographic, and access-to-care factors (Andersen, 1995). According to the model, predisposing 
factors such as demographics, social characteristics, and health beliefs; enabling resources such 
as income, health insurance and other access-to-care indicators; and need for health care as 
perceived by the individual or evaluated by a professional influence health services utilization 
and, in turn, health outcomes such as patient satisfaction, health status etc. (Andersen, 1995). In 
this study, we are studying the impact of major depressive disorder (MDD) (exposure) on the 
survival (outcome) of cancer patients while taking into account some of the demographic and 
socioeconomic factors, which are the predisposing and enabling factors (confounders), and 
assessing whether the number of comorbidities (effect modifier) modifies the impact. We are 
also studying the impact of antidepressant usage on the survival of cancer patients with MDD, 
while adjusting for the predisposing and enabling factors.  
3.3 Hypotheses  
This study has two hypotheses that are reflected in the proposed conceptual frameworks 
(Figures 1 and 2). 
Hypothesis #1. MDD has an impact on survival of cancer patients and this impact varies 
according to the presence of comorbidities, after controlling for sociodemographic and clinical 
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Hypothesis #2. Adequate antidepressant therapy influences the survival of cancer patients with 
MDD and time of MDD diagnosis may modify this influence after controlling for 
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3.4 Study Design and Data Sources 
We used a retrospective cohort design with population-based health administrative data 
available from Institute for Clinical Evaluative Services (ICES) to answer our research questions. 
The participants were identified from a set of linked provincial health care databases available 
from the ICES. All Ontario residents, including immigrants after an initial three-month waiting 
period, are covered by the provincial health insurance program and hence have unique health 
card numbers. ICES collects personally identifiable health-related data from various sources 




(Age, sex, ethnicity) 




Number of comorbidities 
Time of MDD 
diagnosis 
IMPACTS OF DEPRESSION AND ITS MANAGEMENT ON CANCER SURVIVAL 
28 
 
individual in Ontario is assigned a unique ICES code and all personal identifiers are removed 
from the datasets before they become part of the ICES inventory.  
Type of cancer at the time of diagnosis was identified from the Ontario Cancer Registry 
(OCR) using the ICD-O-3 definition (National Cancer Institute, 2008) from the OCR. The 
variable for type of cancer was divided into nine categories: breast, colorectal, digestive system 
except colorectal, female genital, hematological, lung and bronchus, prostate, urinary system, 
and other. Information on stage of cancer was also available, but for a limited number of cases.  
Ontario Marginalization Index (ON-Marg), based on dissemination area and/or census 
tract data as available, has information regarding deprivation or marginalization according to 
demographic characteristics including ethnic concentration quintile, higher values of which 
represent higher concentration of recent immigrants (arrived in Canada in the past 5 years) and 
visible minorities (Matheson et al., 2018). Vital status (dead or alive), nearest neighbourhood 
income quintile, and rurality index were obtained from the Registered Persons Database (RPDB). 
Rurality Index of Ontario scores of 0 to 39 were considered as urban and scores 40 and above 
were considered rural (Glazier et al., 2012). 
Ontario Health Insurance Plan (OHIP) claims database has details about physician visits 
and Discharge Abstract Database (DAD) has hospital admission data. Time of diagnosis of 
depression was obtained from the DAD database. The variable time of depression diagnosis has 
two categories, before cancer diagnosis and after cancer diagnosis. Ontario Drug Benefit claims 
database (ODB) has information about drug claims by ODB beneficiaries such as drug 
identification number, quantity dispensed, and dispensing date. Details about the databases used 
for the study are included in Table 1.  
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The databases from ICES have been used for past research on multimorbidity in Ontario 
(Koné Pefoyo et al., 2015; Mondor et al., 2018; Moin et al., 2018). ICES data has been tested for 
accuracy in identifying chronic conditions such as hypertension (Tu et al., 2007), diabetes (Hux 
et al., 2002), asthma (Gershon et al., 2009a), chronic obstructive pulmonary disease (Gershon et 
al., 2009b), and cardiac conditions such as myocardial infarction, congestive heart failure and 
arrhythmia (Austin et al., 2002). It has been found that the data had sensitivity more than 80% 
and specificity more than 75% for all of those conditions except congestive heart failure and 
arrhythmia which had poor sensitivity at 59% and 61% respectively when they were the main 
reason for hospital stay (Austin et al., 2002). 
The health administrative databases at ICES have information about antidepressant use 
only for those who benefit from the ODB Program. Hence, we examined the effect of 
antidepressant therapy on the survival of ODB beneficiaries who had both cancer and inpatient 
diagnosis of major depressive disorder (MDD). All residents of Ontario become eligible for 
ODB when they become 65 years old (Ontario, 2019). Younger individuals may also be eligible 
for ODB if they are residing in long-term care homes or homes for specialized care or are 
beneficiaries of one of the government-funded services including Home care, Ontario Works, 
Ontario Disability Support Program, Trillium Drug Program, and OHIP+: Children and Youth 
Pharmacare. More than 4,400 prescription drugs are covered under the ODB program (Ontario, 
2019). We did not include the < 65 age group in the analysis for objective #2 because since all 
residents of that age group are not eligible for ODB, the analysis results may not be generalizable 
to everyone in that age group.  
 
 




ICES databases used for obtaining data for the study 
Database Description Variables  
Discharge Abstract 
Database (DAD) 
Information on hospitalizations in 
Ontario. Includes admissions, 
length of stay and discharges. 
Major depressive disorder 




Information on all Ontario 
residents diagnosed with cancer. 
Includes date of diagnosis, site of 
primary cancer and cancer deaths. 
Date of diagnosis, age at 
diagnosis, date of birth, sex, 
primary cancer site, stage at 
diagnosis, date of death 
Ontario Health 
Insurance Plan (OHIP) 
claims database 
Information on claims paid for by 
OHIP. Includes physician visits, 
hospitalizations and associated 
diagnosis.  
Comorbidities including 
depression using the diagnostic 
codes, time of diagnosis 
Registered Persons 
Database (RPDB) 
Demographic information for all 
individuals who have ever had a 
valid Ontario health card number. 
Includes age, sex, neighbourhood 
income and residence.  
Neighbourhood income 




Information on outpatient visits to 
hospital and community-based 
ambulatory care. Includes day 
surgery, outpatient clinics, and 
emergency departments. 
Comorbidities including 
depression using the diagnostic 
codes, time of diagnosis 
Ontario Drug Benefit 
(ODB) claims 
database  
Information about drug claims by 
ODB beneficiaries such as drug 
Antidepressant use from DIN, 
time prescribed, quantity 
dispensed 
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identification number, quantity 




Information regarding deprivation 
or marginalization based on 
residential instability, material 
deprivation, dependency, and 
ethnic concentration 
Ethnic concentration quintile 
 
 
3.5 Ethical Considerations 
This study was part of a larger research project on multimorbidity and cancer. It was 
supported by ICES and funded through a team grant from the Ontario Ministry of Health and 
Long-Term Care. All the researchers involved had valid certificates of completion of Tri-Council 
Policy Statement: Ethical Conduct for Research Involving Humans - Course on Research Ethics 
(TCPS 2: CORE). Ethics approval was obtained from ICES and Lakehead University Research 
Ethics Board before obtaining access to data. ICES has a secure user interface, ICES Data and 
Analytic Services Environment (IDAVE), which provides a virtual desktop infrastructure 
accessible for the researcher using ICES user credentials. The data remains on IDAVE and the 
researcher does all analyses using the software provided in the virtual environment. Hence, 
privacy of the data is ensured by ICES at all times. The data do not contain any identifying 
information and only aggregated results are released back to the researchers for use outside of 
the secure IDAVE environment. 
 
 











Chapter 4: Impact of Depression on the Survival of Cancer patients With and Without 
other Comorbidities: A Population-based Retrospective Cohort Study 
  




Aim: To evaluate the impact of major depressive disorder (MDD) on cancer survival and to 
assess whether the number of other comorbidities modifies the impact. 
Method: A population-based retrospective cohort study was conducted on all adult cancer 
patients diagnosed in Ontario between April 2003 and March 2013, who survived at least a year 
following cancer diagnosis. They were followed until March 2018. Depression was defined as 
having a hospital discharge diagnosis of MDD before or during the study period. Fifteen chronic 
conditions were included for calculating number of comorbidities excluding MDD. Survival 
analysis was performed using Cox proportional hazards regression. 
Results: Among the sample (N=453,012; median age at cancer diagnosis 64 years; 50% female), 
only 2% had MDD diagnosed in hospital. One quarter (25.8%) had 0-1 comorbidities, 38.8% had 
2-3 comorbidities, and 35.4% had ≥ 4 comorbidities other than MDD. MDD was associated with 
a higher risk of mortality (adjusted hazard ratio (aHR) 1.58; 95% confidence interval (CI) 1.54-
1.63). The impact of MDD on mortality varied according to the number of other comorbidities. 
aHR was 2.55 (95% CI 2.31-2.81) for patients with 0-1 comorbidities, 1.85 (95% CI 1.75-1.95) 
for patients with 2-3 comorbidities, and 1.44 (95% CI 1.40-1.49) for patients with ≥ 4 
comorbidities. Stratified analysis by cancer type was performed and showed that there were no 
substantial differences in the impacts of MDD between most cancer types.  
Conclusion: MDD is associated with higher risk of mortality in cancer patients. Impact of MDD 
on cancer survival varies according to number of comorbidities, and is similar across many 
cancer types.  
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Impact of Depression on the Survival of Cancer Patients With and Without Other Chronic 
Diseases: A Population-based Retrospective Cohort Study 
Psychological conditions such as anxiety (Vodermaier et al., 2017) bipolar disorder, and 
depression (Kanani et al., 2016) can influence cancer survival. On average, 8 to 24% of cancer 
patients suffer from depression, although the prevalence varies according to type of cancer 
(Krebber et al., 2014). Depression is associated with delayed cancer diagnosis (O’Rourke et al., 
2008) and reduced adherence to treatment recommendations (Hooper et al., 2016; Moraes & 
Casseb, 2017), diet (Barros et al., 2017) and exercise regimens (Black et al., 2018; Chipperfield 
et al., 2013), which can all contribute to poor survival. Sleep disorders (Nutt et al., 2008) and low 
quality of life (Kenzik et al., 2015; Schoormans et al., 2015) associated with depression can also 
lead to higher mortality among depressed cancer patients. 
Besides depression, the high prevalence of multimorbidity (co-occurrence of more than 
one chronic disease in a person) among cancer patients (Pefoyo et al., 2015) complicates cancer 
and other disease care. Multiple specialties and management modalities are involved in the 
treatment of multimorbid patients. Siloed health systems (Boyd & Fortin, 2010) and practical 
difficulties in effective communication between health care providers (Mc Namara et al., 2017) 
can impact the quality of care received by multimorbid cancer patients. Severity of comorbidities 
(Edwards et al., 2014) and polypharmacy and resulting drug interactions (Riechelmann et al., 
2008; van Leeuwen et al., 2011) may also result in poor survival in cancer patients with other 
chronic conditions. 
Past studies have shown mixed evidence about the impact of depression on cancer 
survival (Faller & Schmidt, 2004; Nakaya et al., 2006; Prasad et al., 2014; Prieto et al., 2005) 
and mostly negative impact of multimorbidity on cancer survival (Parés-Badell et al., 2017; Patel 
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et al., 2017; Phillips et al., 2017). However, there is limited evidence on their combined impact 
(J. Lin et al., 2016), and it is not clear whether the effect of depression is modified by 
multimorbidity. This study aims to quantify the effect of depression on the survival of cancer 
patients in Ontario, Canada, and examines whether this effect is modified by the presence of 
other comorbidities.  
Methods  
Study Design and Data Sources 
A retrospective cohort design was used including population-based health administrative 
data available from the Institute for Clinical Evaluative Sciences (ICES). Canada has a publicly 
funded health care system which ensures universal coverage. All residents of Ontario, including 
immigrants following an initial three-month waiting period, are eligible for the provincial health 
insurance program and hence have unique health card numbers. ICES is a non-profit research 
organization (Institute for Clinical Evaluative Sciences, n.d.a) that collects health-related data in 
Ontario from various sources including physician and hospital records (Institute for Clinical 
Evaluative Sciences, n.d.b). The provincial health insurance claims databases at ICES have 
information about all individuals accessing health care in Ontario, Canada. Various databases 
containing information on the same individual can be linked using the individual’s unique ICES 
code to obtain data regarding inpatient services, outpatient services, and drugs (Institute for 
Clinical Evaluative Sciences, n.d.b). The databases used for this study include Ontario Cancer 
Registry, Ontario Marginalization Index, Registered Persons Database, Ontario Health Insurance 
Plan claims database, Discharge Abstract Database, and National Ambulatory Care Reporting 
System. Details about the databases are included in Appendix A. This study was approved by the 
ICES and Lakehead University Research Ethics Board.  




All adults in Ontario, Canada, aged 18 years or more who were diagnosed with cancer 
from April 1, 2003 to March 31, 2013 were included in the study and followed until March 31, 
2018. Patients who were more than 105 years old and those with invalid health card numbers 
were excluded. Patients who died within one year of cancer diagnosis were also excluded from 
the study to minimize reverse causality.  
Study Measures 
Time of death was identified from the Registered Persons Database to estimate the 
primary outcome, survival time. Survival time represents time from cancer diagnosis to death or 
until March 31, 2018, for those still alive at the end of the study. 
The main exposure, depression, was defined as having major depressive disorder (MDD) 
as one of the diagnoses on a patient’s discharge summary following hospitalization up to three 
years before the study index date or at any point during the follow-up period. MDD was 
identified using the ICD 10 codes F32 (Major depressive disorder, single episode) and F33 
(Major depressive disorder, recurrent) in the Discharge Abstract Database. Number of 
comorbidities excluding depression was included as a potential effect modifier of the impact of 
depression on cancer survival. Fifteen chronic diseases were included in the study: osteoarthritis, 
hypertension, asthma, diabetes, chronic coronary syndrome, cardiac arrhythmia, osteoporosis, 
chronic obstructive pulmonary disease, congestive heart failure, renal failure, dementia, 
rheumatoid arthritis, stroke, acute myocardial infarction, and other mental disorders (substance 
use, psychotic illness, anxiety, other mood disorders, stress, or personality disorder). They were 
selected based on previous research on multimorbidity (Pefoyo et al., 2015). The list of ICD 
codes used for identifying each condition is provided in Appendix B. Other covariates included 
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in the analyses are sociodemographic factors such as age at cancer diagnosis, sex, ethnic 
concentration quintile, neighbourhood income quintile, and rurality of residence and cancer 
characteristics such as type of cancer, and cancer stage. Ethnic concentration quintile was 
obtained from Ontario Marginalization Index and higher values represent higher concentration of 
recent immigrants (arrived in Canada in the past 5 years) and visible minorities (Matheson et al., 
2018). Rurality Index of Ontario scores of 0 to 39 were considered as urban and scores 40 and 
above were considered rural (Glazier et al., 2012).   
Analyses 
All analyses were performed using the statistical analysis software SAS (SAS Institute, 
2013). Chi-square test and ANOVA were conducted to assess the bivariate associations between 
patients’ sociodemographic characteristics (age, sex, ethnicity, income, and rurality), cancer 
characteristics (type of cancer and stage), MDD, and number of other comorbidities and vital 
status. Kaplan-Meier estimates and curves were obtained, and log-rank tests performed, for 
bivariate analysis with survival time. 
Multivariate survival analysis was performed using Cox proportional hazards regression 
to study the adjusted impact of MDD on the risk of death. To investigate whether the impact of 
depression on cancer survival was modified by number of other comorbidities, interaction 
between depression and number of comorbidities other than depression was tested. The 
interaction was statistically significant and hence included in the analyses. Stratified analyses by 
age group (<65 years and ≥ 65 years) was conducted to compare the impact of MDD on the 
survival of younger and older cancer patients. Stratified analysis by cancer type was performed 
to assess whether the impact of MDD on survival varied according to type of cancer. 




Descriptive and Bivariate Analyses 
The sample included 453,012 patients in Ontario, aged 18 or more, who survived at least 
one year after cancer diagnosis. On average a patient was in the study for 7.5 years and 37.9% 
died during the study period. Table 1 shows the characteristics of the whole sample and indicates 
that mortality is associated with each variable. Only 2% of the sample had a hospital discharge 
diagnosis of MDD. Among those with MDD, 62.3% were deceased by the study endpoint 
compared to 37.4% among those without MDD. Multimorbidity was common in the sample with 
35.4% having ≥ 4 chronic diseases besides cancer and MDD.  
The prevalence of each additional chronic disease is listed in Appendix B. Proportion of 
deceased patients increased with the number of chronic diseases, from 25.7% among patients 
with 0 or 1 comorbidity other than MDD to 52.8% among those with ≥ 4 comorbidities.  
 
Table 1 
Characteristics of the sample (Cancer patients aged ≥ 18 years who survived at least a year 











 Mean SD Mean SD Mean SD 
ANOVA 
p-value 
Number of years after 
cancer diagnosis 
7.5 3.8 9.4 2.8 4.4 3.1 <0.0001 
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Age at diagnosis 
(years) 
63.2 14.2 59.1 13.4 69.8 12.8 <0.0001 




18- 64 years 229,697 50.7 176,477 76.8 53,220 23.2  
≥ 65 years 223,315 49.3 104,791 46.9 118,524 53.1  
Major depressive 
disorder (diagnosed at 
any time during the 
study period) 
      <0.0001 
Yes 8,999 2.0 3,396 37.7 5,603 62.3  




(diagnosed at any 
time during the study 
period) 
      <0.0001 
0-1 116,780 25.8 86,829 74.4 29,951 25.7  
2-3 175,854 38.8 118,747 67.5 57,107 32.5  
≥ 4 160,378 35.4 75,692 47.2 84,686 52.8  
Sex       <0.0001 
Female 225,964 49.9 147,033 65.1 78,931 34.9  
Male 227,034 50.1 134,228 59.1 92,806 40.9  





      <0.0001 
Q1 93,918 21.0 54,131 57.6 39,787 42.4  
Q2 90,603 20.2 53,792 59.4 36,811 40.6  
Q3 87,112 19.5 54,318 62.4 32,794 37.7  
Q4 85,270 19.0 54,954 64.5 30,316 35.6  
Q5 91,025 20.3 61,362 67.4 29,663 32.6  
Neighborhood 
income quintile 
      <0.0001 
Q1 80,287 17.8 45,465 56.6 34,822 43.4  
Q2 89,497 19.8 53,502 59.8 35,995 40.2  
Q3 89,011 19.7 55,218 62.0 33,793 38.0  
Q4 93,710 20.8 60,303 64.4 33,407 35.7  
Q5 98,694 21.9 65,688 66.6 33,006 33.4  
Rural       <0.0001 
No 389,767 86.1 244,246 62.7 145,521 37.3  
Yes 62,725 13.9 36,671 58.5 26,054 41.5  
Cancer type       <0.0001 
Breast 77,405 17.1 56,619 73.2 20,786 26.9  
Colon and 
Rectum 
56,897 12.6 30,883 54.3 26,014 45.7  
Digestive 
System, 
21,244 4.7 7,838 36.9 13,406 63.1  







30,739 6.8 20,594 67.0 10,145 33.0  
Hematological 39,841 8.8 22,714 57.0 17,127 43.0  
Lung and 
Bronchus 
29,398 6.5 7,634 26.0 21,764 74.0  
Other 84,797 18.7 58,263 68.7 26,534 31.3  
Prostate 83,415 18.4 60,510 72.5 22,905 27.5  
Urinary 
System 
29,276 6.5 16,213 55.4 13,063 44.6  
Cancer stage       <0.0001 
I 76,985 17.0 59,775 77.6 17,210 22.4  
II 97,798 21.6 69,856 71.4 27,942 28.6  
III 48,880 10.8 24,946 51.0 23,934 49.0  
IV 30,187 6.7 7,799 25.8 22,388 74.2  
Unknown 199,162 44.0 118,892 59.7 80,270 40.3  
aPercentages are column percentages  
bPercentages are row percentages 
 
As shown in Table 2, MDD is associated with all patient characteristics, especially 
number of chronic diseases. Only 0.7% had MDD among patients with 0-1 comorbidities 
whereas 1.5% had MDD among patients with 2-3 comorbidities and 3.5% had MDD among 
IMPACTS OF DEPRESSION AND ITS MANAGEMENT ON CANCER SURVIVAL 
42 
 
patients with 4 or more comorbidities. Prevalence of MDD was higher (more than 2.5%) in 
digestive system except colorectal, hematological, and lung and bronchus cancers. 
Table 2 
Characteristics of the sample according to MDDa (Cancer patients aged ≥ 18 years who 
survived at least a year following cancer diagnosis) 





 Mean SD Mean SD ANOVA 
p-value 
Number of years after 
cancer diagnosis in 
the study 7.6 3.8 6.5 3.8 
<0.0001 






    <0.0001 
0-1 116,007 99.3 773 0.7  
2-3 173,177 98.5 2,677 1.5  
≥ 4 154,829 96.5 5,549 3.5  
Age at diagnosis     <0.0001 
18- 64 years 225,406 98.1 4,291 1.9  
≥ 65 years 218,607 97.9 4,708 2.1  
Sexc     <0.0001 
Female 221,007 97.8 4,957 2.2  
Male 222,992 98.2 4,042 1.8  




quintile     
0.0005 
Q1 91,997 98.0 1,921 2.1  
Q2 88,731 97.9 1,872 2.1  
Q3 85,357 98.0 1,755 2.0  
Q4 83,608 98.1 1,662 2.0  
Q5 89,376 98.2 1,649 1.8  
Neighborhood 
income quintile     
<0.0001 
Q1 78,051 97.2 2,236 2.8  
Q2 87,561 97.8 1,936 2.2  
Q3 87,355 98.1 1,656 1.9  
Q4 92,146 98.3 1,564 1.7  
Q5 97,127 98.4 1,567 1.6  
Rural     <0.0001 
No 382,208 98.1 7,559 1.9  
Yes 61,289 97.7 1,436 2.3  
Cancer type     <0.0001 
Breast 75,922 98.1 1,483 1.9  
Colon and 





and Rectum 20,706 97.5 538 2.5 
 
Female 
Genital 30,142 98.1 597 1.9 
 
Hematological 38,824 97.4 1,017 2.6  
Lung and 
Bronchus 28,538 97.1 860 2.9 
 
Other 83,169 98.1 1,628 1.9  
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Prostate 82,302 98.7 1,113 1.3  
Urinary 
System 28,671 97.9 605 2.1 
 
Cancer stage     <0.0001 
I 75,600 98.2 1,385 1.8  
II 96,159 98.3 1,639 1.7  
III 47,887 98.0 993 2.0  
IV 29,547 97.9 640 2.1  
Unknown 194,820 97.8 4,342 2.2  
aPercentages are row percentages 
Survival Analysis: Kaplan-Meier survival curves (Figure 1) indicate that cancer patients 


















Survival probability of cancer patients aged ≥ 18 years by hospital discharge diagnosis of MDD 
 
 
Analyses also showed that survival varied significantly according to number of 
comorbidities other than MDD (See Appendix C). As shown in Figure 2, survival varied for 
different combinations of MDD and number of other comorbidities. Among those without MDD, 
survival probability was highest among those with 0-1 comorbidities and lowest among ≥ 4 
comorbidities. However, among those with MDD, in the beginning, survival probability was 
highest for patients with ≥ 4 comorbidities, and after around 11 years, survival probability was 
highest for those with 0-1 comorbidities. On further examination, it was found that 26.4% of 
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patients with depression and 0-1 comorbidities had stage III or stage IV cancers whereas it was 
22% for 2-3 comorbidities and 15.1% for 4 or more comorbidities. This might have contributed 
to the lower survival probability for patients with 0-1 comorbidities. Also, for those with 2 or 
more comorbidities, the other comorbidities might have occurred later during the follow-up 
period, hence the greater impact towards the end.  Since Kaplan-Meir curves are only 
descriptive, adjusted analysis using Cox models will be performed to further explore the effect of 
MDD on cancer survival according to number of comorbidities.  
Figure 2 
Survival probability of cancer patients aged ≥ 18 years by MDD and number of comorbidities 
 




Adjusted Impact of MDD on Cancer Survival: The Cox model for studying the overall 
impact of MDD on cancer survival found an adjusted hazard ratio (HR) of 1.58 (95% CI 1.54-
1.63) (results not shown), which means that at any point during the study period a cancer patient 
with MDD was 58% more likely to die than a cancer patient without MDD. Therefore, cancer 
patients with MDD are likely to die faster than those without MDD. Sensitivity analysis was 
conducted by doing stratified Cox regression for those who were in the study for less than five 
years and those who were in the study for five years or more. It showed that depression was not a 
statistically significant predictor for cancer patients who survived less than five years (results not 
shown).  
The impact of MDD varied according to the number of comorbidities (Table 3). The 
impact was highest for patients with 0-1 comorbidities (HR 2.55; 95% CI 2.31-2.81) and lowest 
for patients with ≥ 4 comorbidities other than MDD (HR 1.44; 95% CI 1.40-1.49).  
To understand whether the impact of MDD varied according to age at cancer diagnosis, 
analysis stratified by age group was performed including the interaction variable for MDD and 
number of comorbidities. Among patients with ≥ 4 comorbidities, impact of MDD was higher in 
the <65 years group (HR 1.62; 95% CI 1.52-1.73) than the ≥ 65 years group (HR 1.39; 95% CI 
1.34-1.45) (See Appendix D). At the other two levels of multimorbidity, the confidence intervals 
overlapped implying that there was no significant difference in the impact of MDD on survival 








Adjusted* impact of MDD on mortality for cancer patients aged ≥ 18 years who survived at least 
one year following cancer diagnosis 




0-1 comorbidities (MDD Yes vs No) 2.55 2.31 - 2.81 
2-3 comorbidities (MDD Yes vs No) 1.85 1.75 - 1.95 




18 - 64 years ref  




Male ref  
Female 0.79 0.78 - 0.80 
Ethnic Concentration Quintile 
 
 
Q5 ref  
Q1 1.27 1.25 - 1.29 
Q2 1.27 1.25 - 1.29 
Q3 1.20 1.19 - 1.22 
Q4 1.14 1.12 - 1.16 
Neighborhood income quintile 
 
 
Q5 ref  
Q1 1.29 1.27 - 1.31 
Q2 1.18 1.16 - 1.19 
Q3 1.13 1.11 - 1.14 




No ref  
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Other ref  
Breast 1.00 0.98 - 1.02 
Colon and Rectum 1.14 1.12 - 1.16 
Digestive System, except Colon and 
Rectum 
2.30 
2.26 - 2.35 
Female Genital 1.39 1.36 - 1.42 
Hematological 1.14 1.12 - 1.16 
Lung and Bronchus 2.74 2.69 - 2.80 
Prostate 0.55 0.54 - 0.56 




I ref  
II 1.64 1.60 - 1.67 
III 2.77 2.72 - 2.83 
IV 5.89 5.77 - 6.01 
Unknown 1.91 1.88 - 1.94 
*Result of Cox proportional hazards regression with the interaction term between MDD and 
number of comorbidities and confounding variables included in the model 
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Adjusted Impact of MDD on Cancer Survival Stratified by Cancer Type: Analysis 
stratified by cancer type showed that there were differences in the impact of MDD on survival 
between different types of cancer, although the differences were not statistically significant 
between all cancer types (See Table 4). The impact was highest for prostate cancer patients (HR 
1.92; 95% CI 1.77-2.08) and lowest for lung and bronchus cancer patients (HR 1.20; 95% CI 
1.11-1.30). Interaction between MDD and number of comorbidities showed that the impact of 
MDD did not vary significantly according to number of comorbidities in breast, female genital, 
and lung and bronchus cancers.  
Table 4 
Adjusted impact of MDD on mortality according to type of cancer for patients aged ≥ 18 years 
who survived at least one year following cancer diagnosis, overall (without interaction), and by 
number of comorbidities other than MDD (with interaction between MDD and number of 
comorbidities) 
Cancer type HR 95% CI 
Breasta 1.72 1.59 - 1.85 
Impact of MDD by number of comorbidities 
other than depression* 
  
0-1 comorbidities (MDD Yes vs No) 2.00 1.50 - 2.67 
2-3 comorbidities (MDD Yes vs No) 1.97 1.70 - 2.28 
≥ 4 comorbidities (MDD Yes vs No) 1.62 1.48 - 1.77 
Colon and Rectuma 1.65 1.53 - 1.77 
Impact of MDD by number of comorbidities 
other than depression* 
  
0-1 comorbidities (MDD Yes vs No) 2.58 2.00 - 3.33 
2-3 comorbidities (MDD Yes vs No) 1.78 1.55 - 2.05 
≥ 4 comorbidities (MDD Yes vs No) 1.54 1.41 - 1.68 
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Digestive System, except Colon and Rectumab 1.23 1.11 - 1.36 
Impact of MDD by number of comorbidities 
other than depression* 
  
0-1 comorbidities (MDD Yes vs No) 1.90 1.42 - 2.56 
2-3 comorbidities (MDD Yes vs No) 1.37 1.15 - 1.64 
≥ 4 comorbidities (MDD Yes vs No) 1.08 0.94 - 1.24 
Female Genitala 1.63 1.46 - 1.82 
Impact of MDD by number of comorbidities 
other than depression* 
  
0-1 comorbidities (MDD Yes vs No) 2.05 1.50 - 2.79 
2-3 comorbidities (MDD Yes vs No) 1.91 1.58 - 2.31 
≥ 4 comorbidities (MDD Yes vs No) 1.42 1.21 - 1.65 
Hematologicala 1.55 1.43 - 1.68 
Impact of MDD by number of comorbidities 
other than depression* 
  
0-1 comorbidities (MDD Yes vs No) 3.03 2.26 - 4.07 
2-3 comorbidities (MDD Yes vs No) 1.87 1.60 - 2.17 
≥ 4 comorbidities (MDD Yes vs No) 1.38 1.25 - 1.52 
Lung and Bronchusa 1.20 1.11 - 1.30 
Impact of MDD by number of comorbidities 
other than depression* 
  
0-1 comorbidities (MDD Yes vs No) 1.72 1.28 - 2.31 
2-3 comorbidities (MDD Yes vs No) 1.19 1.03 - 1.39 
≥ 4 comorbidities (MDD Yes vs No) 1.17 1.07 - 1.28 
Othera 1.75 1.64 - 1.87 
Impact of MDD by number of comorbidities 
other than depression* 
  
0-1 comorbidities (MDD Yes vs No) 3.37 2.70 - 4.21 
2-3 comorbidities (MDD Yes vs No) 1.88 1.64 - 2.15 
≥ 4 comorbidities (MDD Yes vs No) 1.60 1.48 - 1.74 
Prostate 1.92 1.77 - 2.08 
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Impact of MDD by number of comorbidities 
other than depression* 
  
0-1 comorbidities (MDD Yes vs No) 3.76 2.45 - 5.78 
2-3 comorbidities (MDD Yes vs No) 2.93 2.48 - 3.47 
≥ 4 comorbidities (MDD Yes vs No) 1.71 1.56 - 1.87 
Urinary Systema 1.56 1.41 - 1.73 
Impact of MDD by number of comorbidities 
other than depression* 
  
0-1 comorbidities (MDD Yes vs No) 1.61 0.98 - 2.64 
2-3 comorbidities (MDD Yes vs No) 1.95 1.53 - 2.49 
≥ 4 comorbidities (MDD Yes vs No) 1.49 1.33 - 1.67 
*Result of Cox proportional hazards regression stratified by cancer type with the interaction term 
between MDD and number of comorbidities and confounding variables (age group, sex, ethnic 
concentration quintile, neighborhood income quintile, rurality of residence, cancer stage) 
included in the model 
aRural not significant 
bNumber of comorbidities not significant 
 
Discussion 
This study examined whether MDD had an impact on the survival of cancer patients with 
or without other comorbidities. The results showed that cancer patients with MDD had a poorer 
survival than those without MDD. However, the impact of MDD on survival was not significant 
for patients who were in the study for less than five years. The overall adjusted impact of 
depression on survival was higher in patients aged < 65 years when compared to those aged ≥ 65 
years.  
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The study results are consistent with the results of past non-Canadian studies that have 
shown that depression has a negative impact on the survival of cancer patients (Chang et al., 
2014; Kanani et al., 2016; Low et al., 2016; Sun et al., 2015; Warnke et al., 2016). The studies by 
Chang et al. (2014) and Sun et al. (2015) were also population-based and included all types of 
cancer. However, they found lower estimates of the impact of depression than this study, most 
likely because they would have included milder cases of depression. Chang et al. (2014) 
identified depression from all psychiatric diagnoses and estimated a 30% higher mortality risk 
(HR 1.30; 95% CI 1.11-1.54) in depressed patients. Sun et al. (2014) identified depression from 
antidepressant use and found that current use was associated with 32% (mortality rate ratio 1.32; 
95% CI 1.29–1.35) higher one-year mortality overall and 22% (mortality rate ratio 1.22; 95% CI 
1.17–1.26) higher five-year mortality among those who survived the first year after cancer 
diagnosis (Sun et al., 2015). Various meta-analyses examining the impact of depression on 
cancer survival have also shown that depression is associated with a higher risk of death 
(Pinquart & Duberstein, 2010; Satin et al., 2009; Wang et al., 2019).  
The meta-analysis by Pinquart & Duberstein found that studies with shorter follow-up 
period (2 years or less) and in older patients showed stronger association between depression and 
cancer survival (Pinquart & Duberstein, 2010). This is in contrast with our study since our results 
showed no association between depression and cancer survival in those who survived less than 
five years (although we excluded patients who survived less than a year after cancer diagnosis) 
and lesser impact of depression on the survival of cancer patients in the older compared to the 
younger age group. In Ontario all residents become eligible for prescription drug coverage 
through ODB when they turn 65 years of age, increasing the likelihood of filling antidepressant 
prescriptions by that age group. Hence their depression may be better controlled resulting in the 
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reduced impact of depression on their survival. Similar to our study, Prieto et al. (2005) also 
found no significant association between depression and five-year survival although their sample 
included only hematological cancer patients with stem-cell transplantation. 
Prevalence of multimorbidity was high in the sample, with 74% patients having 2 or 
more comorbidities other than MDD. Number of comorbidities had a modifying effect on the 
impact of MDD on cancer survival. Patients with 0-1 comorbidities showed the highest impact of 
MDD on survival and patients with ≥ 4 comorbidities showed the lowest impact. The reason 
might be that the severity of other comorbidities had a greater impact on survival than MDD in 
patients with more comorbidities. Since we did not include the severity of comorbidities in our 
analyses it is not possible to ascertain whether that is the reason for the decreased impact of 
depression on survival when the number of other comorbidities increased. Another reason might 
be the frequent health system encounters due to higher number of comorbidities leading to earlier 
diagnosis (Akincigil & Matthews, 2017) and better management of MDD. 
There was a higher prevalence of MDD in cancers of poorer prognosis, although the 
impact of MDD on survival in such cancer types was lower. Because of clinical differences, 
cancer types might influence the impact of MDD on survival. Stratified analysis showed that in 
breast, colorectal, female genital, prostate, and ‘other’ cancers, patients with MDD had more 
than 60% higher mortality than those without MDD. Routine screening can lead to earlier 
diagnosis of breast, prostate, colorectal and cervical cancers resulting in a better prognosis. The 
reason why the impact of depression on survival is higher in those patients may be that because 
they are likely to live longer, there is a longer timespan in which depression can influence the 
patients’ health-related behaviors, such as adherence to treatment and maintaining a healthy 
lifestyle, which in turn can affect their longevity. Other studies have also shown that depression 
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is associated with higher mortality among those cancer types (Liang et al., 2017; P.-H. Lin et al., 
2018; Lu et al., 2019; Suppli et al., 2017; Vodermaier et al., 2014). Similar to our findings, 
population-based studies in British Columbia, Canada, have also reported that depression was 
associated with poorer survival among lung (Vodermaier et al., 2017) and breast cancer patients 
(Vodermaier et al., 2014). Lowest impact of MDD on survival was found in digestive system 
except colorectal and in lung and bronchus cancers, although patients with those types of cancers 
had a higher prevalence of MDD. Those cancer types also had the highest percentage of 
deceased patients. The greater severity and overall poorer prognosis for those cancer types might 
have impacted the mental health of the patients and contributed to increased risk of MDD, 
without MDD being the main reason of death. It can be inferred that the lower survival time for 
those patients limited the duration of effect of MDD and hence the lower impact of MDD on 
survival.   
Overall, in all types of cancer, the highest impact of MDD on survival was in patients 
with 0-1 comorbidities and lowest impact in patients with ≥ 4 comorbidities, although the 
differences in impact according to multimorbidity was not significant for breast, female genital, 
and lung and bronchus cancers. A study in the USA investigating the impact of pre-existing 
mental health disorders on lung cancer survival showed that the impact was statistically 
significant in patients with no comorbidities (HR 1.15, 95% CI 1.01-1.31) and one comorbidity 
(HR 1.18, 95% CI 1.01-1.39) and not significant in those with 2 or more comorbidities (HR 1.07, 
95% CI 0.95-1.20) (J. Lin et al., 2016). Our study showed a significant impact of MDD on the 
survival of lung and bronchus cancer patients at all the three levels of multimorbidity, although 
difference between the impacts of MDD at different levels of multimorbidity was not statistically 
significant. Our study differed from the study by J. Lin et al. (2016) in that their sample was 
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from the military health system who typically have a high prevalence of mental health disorders 
and substance abuse (Hoge et al., 2004). Their exposure was any pre-existing mental health 
disorder, including post-traumatic stress disorder and psychotic disorder, whereas our exposure 
was MDD diagnosed both before and after cancer diagnosis. Their analyses were adjusted for 
confounders such as smoking, marital status, tumor grade and histology, types of treatment, and 
recurrence status.    
Overall, this study showed that MDD was a key predictor of cancer survival. More 
generally, however, mental health needs of cancer patients can be complex as evidenced by 40% 
of the whole sample and 80.7% of patients with MDD having a mental health disorder besides 
MDD (See Appendix B). Hence, mental health care is important in the management of cancer 
patients.  
Limitations 
This study may be subject to misclassification bias due to methods used for identifying 
depression and other health conditions and accuracy of coding in the administrative data. If the 
patient or the physician does not give importance to mental health symptoms, depression may 
not be recognized. We could only include the diagnosis of MDD in hospitalized patients 
(identified using ICD 10 codes) for this study since the ICD 9 codes recorded for outpatient visits 
did not have more than three digits, preventing the identification of MDD separate from other 
episodic mood disorders. This has resulted in underestimating the depression prevalence. In 
hospitalized patients, a mental health diagnosis is likely to be specified only if it is very apparent 
and not well-controlled, which could also lead to underestimation of depression. In other words, 
we recognize that our analysis likely reflects the impact of severe depression, as mild and 
moderate depression is unlikely to be diagnosed in hospital. The annual prevalence of major 
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depression in Canada is around 5% (Patten et al., 2016), which is significantly higher than our 
estimate. 
Since many patients included in the non-exposed group (no MDD) might have had 
outpatient diagnosis of MDD, the resulting misclassification bias might have attenuated the study 
estimates (type II error). If all patients with MDD (diagnosed in hospital as well as outpatient 
settings) had been included in the exposed group, the HR estimates would likely be higher, 
although there is a chance that less severe MDD diagnosed in outpatient settings may not have as 
high an impact on survival as MDD diagnosed during hospitalizations. Another problem 
associated with identifying MDD only in hospitalized patients is that generally cancer patients 
are hospitalized when they have severe symptoms and there is a high rate of in-hospital deaths in 
cancer patients who are hospitalized (Numico et al. 2015). Hence, the patients identified as 
having MDD in this study might have been already in a critical condition to warrant 
hospitalization. So, there is a possibility of reverse causality in this study. There is also the 
possibility of differential misclassification since patients who are more likely to have the 
outcome (death) are also more likely to be diagnosed with MDD during a hospitalization 
(exposure). 
There are other chronic diseases, such as genetic disorders and congenital malformations, 
which were not included and hence the number of comorbidities in our study population might 
be an underestimation. The study did not consider the severity of comorbidities for estimating 
the level of multimorbidity. A patient with one severe chronic disease may have shorter survival 
than a patient with three chronic diseases that are well-controlled. Information regarding 
confounders such as marital status, diet, physical activity, smoking, and alcohol use were not 
available and hence we were unable to adjust the analyses for those confounders. Other potential 
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confounders which were not included are health care related factors such as access to care and 
quality of care. 
Strengths 
The large sample size of our study minimizes selection bias and facilitates decision-
making better than studies on smaller samples. The longer follow-up period (7.5 years in 
average) is another strength of this study, which allowed the assessment of longer-term survival 
among cancer patients. The results of stratified analyses may help in developing specially 
tailored programs for improving the survival of cancer patients according to multimorbidity and 
cancer type.  
Conclusions 
This study showed that depression has a negative impact on the survival of cancer 
patients in Ontario and that the impact varies according to the number of other comorbidities 
present in a patient. The results stress the importance of identifying and properly addressing 
depression in cancer patients, especially in the context of multimorbidity. The finding that MDD 
impacts survival in all cancer types, even if the impact in cancers with poorer survival is smaller, 
emphasizes that depression should be diagnosed and treated in patients with all types of cancer. 
Proper diagnosis and treatment of cancer patients with MDD may improve their adherence to 
treatment and lifestyle recommendations and quality of life, leading to longer survival. Future 
studies should investigate the combined impact of all mental health disorders on cancer and 
multimorbidity survival as mental health disorders of all kinds and their treatment are likely to 
affect outcomes of cancer patients.  
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ICES databases used for obtaining data for the study 
Database Description Variables  
Discharge Abstract 
Database (DAD) 
Information on hospitalizations in 
Ontario. Includes admissions, 
length of stay and discharges. 
Major depressive disorder 




Information on all Ontario 
residents diagnosed with cancer. 
Includes date of diagnosis, site of 
primary cancer and cancer deaths. 
Age at diagnosis, sex, primary 
cancer site, stage at diagnosis, 
time of death 
Ontario Health 
Insurance Plan (OHIP) 
claims database 
Information on claims paid for by 
OHIP. Includes physician visits, 
hospitalizations and associated 
diagnosis.  
Comorbidities including 
depression using the diagnostic 
codes, time of diagnosis 
Registered Persons 
Database (RPDB) 
Demographic information for all 
individuals who have ever had a 
valid Ontario health card number. 
Includes age, sex, neighbourhood 
income and residence.  
Neighbourhood income 




Information on outpatient visits to 
hospital and community-based 
ambulatory care. Includes day 
surgery, outpatient clinics, and 
emergency departments. 
Comorbidities including 
depression using the diagnostic 




Information regarding deprivation 
or marginalization based on 
residential instability, material 
Ethnic concentration quintile 
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deprivation, dependency, and 
ethnic concentration 
  




ICD codes and prevalence of chronic conditions  




410 I21, I22 4.41 
Arthritis - 
Osteoarthritis 




714 M05-M06 3.25 
Asthma 493 J45 14.19 




Cardiac Arrythmia 427.3 (DAD) / 427 (OHIP) I48.0, I48.1 13.43 
Congestive heart 
failure 
428 I500, I501, 
I509 
13.86 
COPD 491, 492, 496 J41, J43, J44 13.69 
Dementia 290, 331, 797 (OHIP) / 
290.0, 290.1, 290.3, 290.4, 
290.8, 290.9, 294.1, 294.8, 























 F32, F33  1.99 
Diabetes 250 E08 - E13 28.57 
Hypertension 401, 402, 403, 404, 405 I10, I11, I12, 
I13, I15 
62.99 
Osteoporosis 733 M81 M82 7.64 





















291, 292, 303, 304, 305, 






















Adjusted impact* of MDD on mortality for cancer patients aged ≥ 18 years who survived at least 
one year following cancer diagnosis, stratified by age group with interaction of MDD and 
number of comorbidities 
 < 65 years ≥ 65 years 
Variable HR 95% CI HR 95% CI 
MDD 
 
   
0-1 comorbidities (MDD Yes vs No) 2.46 2.19 - 2.77 2.57 2.13 - 3.10 
2-3 comorbidities (MDD Yes vs No) 1.84 1.71 - 1.98 1.77 1.64 - 1.91 
≥ 4 comorbidities (MDD Yes vs No) 1.62 1.52 - 1.73 1.39 1.34 - 1.45 
Sex     
Male ref    
Female 0.72 0.70 - 0.73 0.84 0.83 - 0.85 
Ethnic Concentration Quintile     
Q5 ref    
Q1 1.30 1.26 - 1.34 1.23 1.21 - 1.26 
Q2 1.27 1.24 - 1.31 1.25 1.23 - 1.28 
Q3 1.19 1.16 - 1.23 1.20 1.18 - 1.22 
Q4 1.13 1.10 - 1.16 1.14 1.12 - 1.16 
Neighborhood income quintile     
Q5 ref    
Q1 1.32 1.29 - 1.36 1.27 1.24 - 1.29 
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Q2 1.23 1.20 - 1.27 1.15 1.13 - 1.17 
Q3 1.17 1.14 - 1.20 1.11 1.09 - 1.13 
Q4 1.10 1.07 - 1.13 1.06 1.04 - 1.08 
Rural     
No ref    
Yes 1.04 1.01 - 1.07 1.00 0.98 - 1.01 
Cancer type     
Other ref    
Breast 1.31 1.26 - 1.35 0.82 0.80 - 0.84 
Colon and Rectum 1.56 1.51 - 1.61 0.93 0.91 - 0.95 
Digestive System, except Colon and Rectum 3.40 3.28 - 3.52 1.78 1.73 - 1.82 
Female Genital 1.92 1.85 - 2.00 1.13 1.09 - 1.16 
Hematological 1.21 1.17 - 1.25 1.05 1.03 - 1.08 
Lung and Bronchus 4.60 4.46 - 4.75 2.11 2.06 - 2.16 
Prostate 0.48 0.46 - 0.50 0.52 0.51 - 0.53 
Urinary System 1.25 1.20 - 1.30 0.94 0.92 - 0.97 
Cancer Stage     
I ref    
II 2.14 2.06 - 2.22 1.44 1.41 - 1.47 
III 4.27 4.11 - 4.42 2.22 2.16 - 2.27 
IV 9.89 9.53 - 10.26 4.35 4.24 - 4.47 
Unknown 2.33 2.25 - 2.41 1.72 1.69 - 1.76 
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*Result of Cox proportional hazards regression with the interaction term between MDD and 



















Chapter 5: Impact of Adequate Antidepressant Refill on the Survival of Older Cancer 
Patients with Depression 
  




Aim: To evaluate the impact of adequate antidepressant refill (AAR – defined as 180 days’ 
continuous refill of antidepressants) on the survival of older cancer patients with major 
depressive disorder (MDD). 
Methods: A population-based retrospective cohort study was conducted on all cancer patients 
aged ≥ 65 years in Ontario, Canada, who were diagnosed with cancer between April 2003 and 
March 2013, survived at least a year following cancer diagnosis, and had a hospital discharge 
diagnosis of MDD before or during the study period. They were followed until March 2018. Cox 
proportional hazards regression was performed adjusting for covariates. 
Results: Among the sample (N=4,708; 51.5% females; median age at cancer diagnosis 75 years), 
67.7% were diagnosed with MDD after cancer. 76.9% died during the study and 65.5% received 
AAR. Overall, AAR was associated with lower risk of mortality (adjusted hazard ratio (aHR) 
0.58; 95% confidence interval (CI) 0.54-0.62). Further testing showed that the impact of AAR on 
mortality was statistically significant only for patients whose MDD was diagnosed after cancer 
(aHR 0.51; 95% CI 0.47-0.55). Analysis stratified by cancer type showed that the impact of 
AAR on mortality did not vary significantly between all cancer types. In patients whose MDD 
was diagnosed before cancer, AAR had a statistically significant impact only in lung and 
bronchus cancers and digestive system cancers except colorectal. Among patients whose MDD 
was diagnosed after cancer, AAR was associated with lower mortality in all cancer types.  
Conclusion: AAR is associated with better survival among cancer patients with MDD if MDD is 
diagnosed after cancer.  
IMPACTS OF DEPRESSION AND ITS MANAGEMENT ON CANCER SURVIVAL 
78 
 
Impact of Adequate Antidepressant Refill on the Survival of Older Cancer Patients with 
Depression 
Depression is a mood disorder which affects cancer patients more than the rest of the 
population (Watts et al., 2015). Depending on the severity of cancer, prevalence of depression 
among cancer patients ranges from 5% to 50% (Walker et al., 2013). Depression is associated 
with lesser likelihood for undergoing cancer screening (Silberbogen et al., 2014) and receiving 
definitive treatments for cancer (Prasad et al., 2014). They are also likely to have poor adherence 
to treatment recommendations (Moraes & Casseb, 2017). Depressed patients are at a high risk of 
having unhealthy behaviours such as poor diet, alcoholism, (Barros et al., 2017), smoking, drug 
use (Ruggles et al., 2017), and physical inactivity (Chipperfield et al., 2013), which can impact 
their survival. Studies have shown that depression can negatively impact the survival of cancer 
patients (Chang et al., 2014; Shinn et al., 2016). 
Depression in cancer patients can be managed by using antidepressants or employing 
psychological or psychosocial interventions (Li et al., 2016) and treatment of depression can 
improve the quality of life among cancer patients (Nikbakhsh et al., 2018). Antidepressant 
therapy is considered as a first-line treatment for severe depression in cancer patients (Li et al., 
2016). It is recommended that a patient should take an antidepressant dose for around one to two 
months to attain its full benefits (American Psychiatric Association, 2010) and continue using the 
antidepressant for at least six months following symptom remission (National Health Service, 
2018).  
More than 50% of new cancer diagnoses occur in those who are 65 years of age or older 
(National Cancer Institute, 2015). Among older cancer patients, the prevalence of clinical 
depression ranges from 3% to 25% according to a review of literature (Kua, 2005). Non-
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pharmacological methods for managing depression including problem-solving therapy and 
cognitive behavioral therapy have been found to be beneficial in older patients with depression 
(Jonsson et al., 2016). First-line antidepressants recommended in older patients such as selective 
serotonin reuptake inhibitors (SSRIs) and selective serotonin noradrenaline reuptake inhibitors 
(SSNRIs) have been found to have similar risk of mortality as citalopram, which is a commonly 
prescribed SSRI (Kollhorst et al., 2019). 
There are some risks associated with antidepressant use in cancer patients. SSRI use has 
been found to be associated with higher mortality among breast cancer patients (Busby et al., 
2018) and with faster disease progression among ovarian cancer patients (Christensen et al., 
2016). Studies among lung cancer patients have shown conflicting results about the impact of 
antidepressant use on survival (Sullivan et al., 2014; Zingone et al., 2017). Hence, 
antidepressants are prescribed to cancer patients only when the benefits outweigh the risks (Li et 
al., 2016). 
Although there are studies on the impacts of different types of depression treatment in 
older patients (Jonsson et al., 2016; Kollhorst et al., 2019) and in cancer patients (Okuyama et 
al., 2017; Ostuzzi et al., 2018), there is a paucity of research examining the impact of 
antidepressant use in older cancer patients with depression (Ostuzzi et al., 2018). This study aims 
to estimate the impact of adequate antidepressant refill (AAR) on the survival of older cancer 
patients with depression, specifically major depressive disorder (MDD). 
Methods 
Study Design and Data Sources 
The population-based health administrative data available from the Institute for Clinical 
Evaluative Sciences (ICES) were used to conduct retrospective cohort study in Ontario, Canada. 
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ICES, which is a non-profit research organization (Institute for Clinical Evaluative Sciences, 
n.d.a), collects health care data of Ontario residents from various sources such as physician and 
hospital records (Institute for Clinical Evaluative Sciences, n.d.b). Different databases 
maintained at ICES were linked using the patients’ unique ICES codes to obtain information 
about inpatient services, outpatient services, and drugs (Institute for Clinical Evaluative 
Sciences, n.d.b). The databases used include Ontario Cancer Registry, Ontario Marginalization 
Index, Registered Persons Database, Ontario Health Insurance Plan claims database, Discharge 
Abstract Database, Ontario Drug Benefit claims database and National Ambulatory Care 
Reporting System. See Appendix A for details about the databases used for the study. Ethics 
approval was obtained from ICES and Lakehead University Research Ethics Board.  
Study Population 
All cancer patients in Ontario diagnosed between April 1, 2003 and March 31, 2013 who 
were at least 65 years old and had a hospital discharge diagnosis of MDD were included in the 
study. All Ontario residents become eligible for provincial drug coverage under the Ontario Drug 
Benefit (ODB) program when they become 65 years old (Ontario, 2019) and information about 
drug refills is available from the ODB database for that age group. The cohort was followed until 
March 31, 2018 to measure survival. MDD was identified using the ICD 10 codes F32 (Major 
depressive disorder, single episode) and F33 (Major depressive disorder, recurrent) from the 
Discharge Abstract Database on hospitalized patients at any point during the study period or up 
to three years before the beginning of the study. Patients who were more than 105 years old and 
those with invalid health card numbers were excluded. Patients who died within one year of 
cancer diagnosis were also excluded from the study to minimize reverse causality.  
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There were 334,740 cancer patients, 65 years or older, who were diagnosed with cancer 
between April 1, 2003 and March 31, 2013. Among them, 7,254 (2.17%) had a hospital 
discharge diagnosis of MDD. The study sample was obtained after excluding 2,546 patients 
(35.1% of patients with MDD) who died within one year of cancer diagnosis. Average age at 
cancer diagnosis was 77.9 years for the patients who died within a year of cancer diagnosis and 
18.5% had stage IV cancer. Stage was unknown for 64.7% of those patients. 
Study Measures 
The primary outcome, survival time, was available from the Registered Persons 
Database. Survival time represents number of days from cancer diagnosis to death or until March 
31, 2018, for those still alive at the end of the study. 
The main exposure, adequate antidepressant refill (AAR), was defined as 180 days of 
continuous antidepressant refill with no more than 7 days’ gap. Adequate antidepressant use was 
defined as taking antidepressant for 180 days or more, since six months is the recommended 
minimum duration of antidepressant therapy (Duhoux et al., 2012; National Health Service, 
2018). Antidepressants included in this study and their drug identification numbers (DINs) are 
listed in Appendix B. ODB database has information such as name of medication, DIN, time of 
fill, and number of days’ supply refilled each time, which were used to identify AAR. 
Time of MDD (before/after cancer diagnosis) was included as a potential effect modifier 
of the impact of AAR on survival. Sociodemographic factors such as age at cancer diagnosis, 
sex, ethnic concentration quintile, neighbourhood income quintile, and rurality of residence and 
clinical factors such as type of cancer, cancer stage, and number of comorbidities other than 
MDD were included as confounders. Higher values in the ethnic concentration quintile represent 
higher concentration of recent immigrants (arrived in Canada in the past 5 years) and visible 
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minorities (Matheson et al., 2018). Rurality Index of Ontario scores of 0 to 39 were considered 
as urban and scores 40 and above were considered rural (Glazier et al., 2012). The following 
chronic diseases were counted for estimating the number of comorbidities other than MDD based 
on previous research on multimorbidity: osteoarthritis, hypertension, asthma, diabetes, chronic 
coronary syndrome, cardiac arrhythmia, osteoporosis, chronic obstructive pulmonary disease, 
congestive heart failure, renal failure, dementia, rheumatoid arthritis, stroke, acute myocardial 
infarction, and other mental disorders (substance use, psychotic illness, anxiety, other mood 
disorders, stress, or personality disorder).  previous research on multimorbidity (Pefoyo et al., 
2015).  
Analyses 
All analyses were performed using the statistical analysis software SAS (SAS Institute, 
2013). Chi-square test and ANOVA were used to assess the bivariate associations between 
patients’ sociodemographic characteristics (age, sex, ethnicity, income, rurality (rural/not rural)), 
cancer characteristics (type of cancer and stage), number of comorbidities, time of MDD 
diagnosis, and AAR and vital status. Kaplan-Meier estimates and curves were obtained and log-
rank tests performed for bivariate analysis with survival time. 
Multivariate analysis was performed using Cox proportional hazards regression to study 
the adjusted impact of AAR on the risk of death. Interaction of AAR and time of diagnosis of 
MDD was tested for to examine whether the impact of AAR on survival varied according to time 
of MDD diagnosis. Since survival varies according to clinical characteristics, stratified analysis 
for specific types of cancer was conducted to estimate the impact of AAR on the survival of 
specific cancer types after testing for the effect of interaction between AAR and cancer type.  




Descriptive and Bivariate Analyses 
The sample included 4,708 cancer patients aged ≥ 65 years with a hospital discharge 
diagnosis of MDD. Table 1 shows the characteristics of the whole sample and according to the 
outcome, death. On average, patients were in the study for 5.8 years. MDD was diagnosed after 
cancer diagnosis in 67.7% of the sample, and 65.5% of the sample received AAR. Overall, 77% 
died during the study period. Among those who received AAR, 71% died within the study 
period. Among those who did not receive AAR, 88% died during the study.    
Table 1 
Characteristics of cancer patients with MDD aged ≥ 65 who survived at least a year following 










Mean SD Mean SD Mean SD ANOVA 
p-value 
Number of years in 
the study 5.8 3.6 9.3 2.8 4.8 3.1 
<0.0001 
Age at cancer 










AAR       <0.0001 
No 1,624 34.5 193 11.9 1,431 88.1  
Yes 3,084 65.5 896 29.1 2,188 71.0  
Time of MDD 
diagnosis       
<0.0001 




diagnosis 1,525 32.4 436 28.6 1,089 71.4 
 
After cancer 
diagnosis 3,183 67.6 653 20.5 2,530 79.5 
 
Sex       0.0015 
Female 2426 51.5 607 25.0 1,819 75.0  
Male 2,282 48.5 482 21.1 1,800 78.9  
Ethnic concentration 
quintile       
0.7872 
Q1 
1,079 23.3 260 24.1 819 75.9 
 
Q2 
1,017 21.9 225 22.1 792 77.9 
 
Q3 
897 19.3 201 22.4 696 77.6 
 
Q4 
846 18.2 201 23.8 645 76.2 
 
Q5 
802 17.3 190 23.7 612 76.3 
 
Neighborhood 
income quintile       
0.2292 
Q1 
1,129 24.1 257 22.8 872 77.2 
 
Q2 
987 21.0 246 24.9 741 75.1 
 
Q3 
856 18.2 181 21.1 675 78.9 
 
Q4 
846 18.0 186 22.0 660 78.0 
 
Q5 
874 18.6 216 24.7 658 75.3 
 
Rural       0.8698 
No 3,945 83.9 914 23.2 3,031 76.8  
Yes 760 16.2 174 22.9 586 77.1  
Cancer type       <0.0001 
Breast 696 14.8 218 31.3 478 68.7  










240 5.1 32 13.3 208 86.7 
 
Female 
Genital 235 5.0 63 26.8 172 73.2 
 
Hematological 477 10.1 92 19.3 385 80.7  
Lung and 
Bronchus 505 10.7 66 13.1 439 86.9 
 
Other 660 14.0 143 21.7 517 78.3  
Prostate 771 16.4 231 30.0 540 70.0  
Urinary 
System 363 7.7 73 20.1 290 79.9 
 
Cancer stage       <0.0001 
I 
649 13.8 217 33.4 432 66.6 
 
II 
909 19.3 268 29.5 641 70.5 
 
III 
474 10.1 89 18.8 385 81.2 
 
IV 
270 5.7 35 13.0 235 87.0 
 
Unknown 




than depression       
0.0003 
< 4 1,069 22.7 291 27.2 778 72.8  
≥ 4 
3,639 77.3 798 21.9 2,841 78.1  
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While 82.5% of cancer patients whose MDD was diagnosed before cancer diagnosis 
received AAR, only 57.4% of patients whose MDD was diagnosed after cancer received AAR. 
There was no significant difference between patients who received AAR and those who did not 
receive AAR in terms of age and socioeconomic factors such as ethnic concentration quintile, 
neighborhood income quintile, and rurality of residence (Table 2). Nonetheless, we still included 
those variables in the analyses because those characteristics can impact cancer survival. 
There was a significant difference between those who received AAR and those who did 
not receive AAR in cancer characteristics such as type of cancer at the time of diagnosis and 
stage at the time of diagnosis. Percentage receiving AAR varied from 54.6% in patients with 
digestive system cancer (except colorectal) to 74.4% in patients with breast cancer. Lesser 
proportion of patients diagnosed with late-stage cancers received AAR compared to patients 
diagnosed with early-stage cancers (Table 2). 
Table 2 
Characteristics of cancer patients with MDD aged 65 or above who survived at least a year 
following cancer diagnosis, according to adequate antidepressant refill 
Variable 
No AAR (N=1,624; 
34.5%) AAR (N=3,084; 65.5%) 
 
 
Mean SD Mean SD ANOVA p-
value 
Number of years in the 
study 4.8 3.3 6.3 3.6 
<0.0001 
Age (years) 75.4 6.8 75.6 7.0 0.3392 
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Time of MDD 
diagnosis     
<0.0001 
Before cancer 
diagnosis 267 17.5 1,258 82.5 
 
After cancer 
diagnosis 1,357 42.6 1,826 57.4 
 
Sex     <.0001 
Female 751 31.0 1,675 69.0  
Male 873 38.3 1,409 61.7  
Ethnic concentration 
quintile     
0.5153 
Q1 368 34.1 711 65.9  
Q2 342 33.6 675 66.4  
Q3 311 34.7 586 65.3  
Q4 287 33.9 559 66.1  
Q5 299 37.3 503 62.7  
Neighborhood income 
quintile     
0.3095 
Q1 370 32.8 759 67.2  
Q2 328 33.2 659 66.8  
Q3 304 35.5 552 64.5  
Q4 296 35.0 550 65.0  
Q5 322 36.8 552 63.2  
Rural     0.4879 
No 1,370 34.7 2,575 65.3  
Yes 254 33.4 506 66.6  
Cancer type      <0.0001 
Breast 178 25.6 518 74.4  
Colon and 
Rectum 273 35.9 488 64.1 
 






Rectum 109 45.4 131 54.6 
 
Female Genital 85 36.2 150 63.8  
Hematological 176 36.9 301 63.1  
Lung and 
Bronchus 185 36.6 320 63.4 
 
Other 229 34.7 431 65.3  
Prostate 268 34.8 503 65.2  
Urinary System 121 33.3 242 66.7  
Cancer stage     <0.0001 
I 179 27.6 470 72.4  
II 295 32.5 614 67.5  
III 190 40.1 284 59.9  
IV 141 52.2 129 47.8  
Unknown 819 34.0 1,587 66.0  
Number of 
comorbidities other 
than MDD     
<0.0001 
< 4 502 47.0 567 53.0  
≥ 4 1,122 30.8 2,517 69.2  
 
Survival analysis: Kaplan-Meier curves (Figure 1) suggest that cancer patients with 
MDD had a higher survival probability if they received AAR (<0.001). Patients who were 
diagnosed with MDD after cancer and did not receive AAR had the lowest survival probability. 
They had worse survival than patients who were diagnosed with MDD before cancer irrespective 
of whether patients who were diagnosed with MDD before cancer received AAR or not. Patients 
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Survival probability of cancer patients aged ≥ 65 years with MDD who survived at least a year 









Impact of AAR on the Survival of Cancer Patients with MDD: Adjusted Cox 
proportional hazards regression showed that those who received AAR had 42% lower risk of 
death (HR 0.58; 95% CI 0.54-0.62) than those who did not receive AAR (results not shown). 
However, when an interaction between AAR and time of MDD diagnosis was included in the 
analysis, the impact was significant only for patients whose MDD was diagnosed after cancer 
(HR 0.51; 95% CI 0.47-0.55) (Table 3). 
Table 3 
Adjusted impact* of AAR on the survival of cancer patients aged ≥ 65 years with MDD who 
survived at least a year following cancer diagnosis 
Variable HR 95% CI 
Impact of AAR by time of MDD diagnosis 
 
  
Before cancer diagnosis (AAR Yes vs No) 0.89 0.76 1.04 
After cancer diagnosis (AAR Yes vs No) 0.51 0.47 0.55 
Age 1.05 1.04 1.05 
Sex    
Male ref   
Female 0.79 0.72 0.85 
Ethnic concentration quintile    
Q5 ref   
Q1 0.98 0.87 1.10 
Q2 1.07 0.95 1.19 
Q3 1.05 0.94 1.17 
Q4 0.99 0.89 1.11 
Neighborhood income quintile    
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Q5 ref   
Q1 1.06 0.95 1.17 
Q2 1.05 0.95 1.18 
Q3 1.10 0.98 1.22 
Q4 1.05 0.94 1.17 
Rural    
No ref   
Yes 1.01 0.92 1.12 
Cancer type    
Other ref   
Breast 0.84 0.73 0.96 
Colon and Rectum 0.85 0.75 0.96 
Digestive System, except Colon and Rectum 1.33 1.13 1.57 
Female Genital 1.00 0.83 1.20 
Hematological 1.04 0.91 1.19 
Lung and Bronchus 1.64 1.44 1.88 
Prostate 0.63 0.55 0.72 
Urinary system 0.95 0.82 1.09 
Cancer stage at diagnosis    
I ref   
II 1.22 1.07 1.38 
III 1.68 1.46 1.93 
IV 2.43 2.06 2.87 
Unknown 1.19 1.06 1.33 
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Number of comorbidities other than MDD    
< 4 ref   
≥ 4 1.03 0.95 1.11 
*Result of Cox proportional hazards regression with the interaction term between AAR and time 
of MDD diagnosis and confounding variables included in the model 
On further examination, it was found that of the 42.6% patients whose MDD was 
diagnosed after cancer and did not receive AAR, 22.9% did not survive for 180 days after MDD 
diagnosis. Hence, unless they had an outpatient diagnosis of MDD before the hospital diagnosis 
of MDD, they were not in the study long enough after their MDD diagnosis to complete 180 
days’ continuous antidepressant refill. Sensitivity analysis was conducted excluding patients who 
were in the study for less than a year following MDD diagnosis. Results showed that those who 
received AAR still had a lower risk of mortality compared to those who did not receive AAR 
(HR 0.87; 95% CI 0.79-0.96), although when interaction term of AAR and time of MDD 
diagnosis was included in the model, the impact was significant only for patients whose MDD 
was diagnosed after cancer (HR 0.86; 95% CI 0.76-0.98). 
Impact of AAR on the Survival of Cancer Patients with MDD according to Cancer 
Type: Result of adjusted Cox regression stratified by cancer type showed that for all types of 
cancer, those who received AAR had a lower risk of mortality than those who did not receive 
AAR, although the impact was not significant for cancer of digestive system, except colorectal 
(Table 4). The impact was highest for urinary system cancer (HR 0.43; 95% CI 0.33-0.55). 
Having ≥ 4 comorbidities was associated with better survival in patients among digestive system, 
except colorectal, (HR 0.52; 95% CI 0.38-0.71) and lung and bronchus (HR 0.76; 95% CI 0.60-
0.97) cancers. Only digestive system cancer except colorectal showed a statistically significant 
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difference in the impact of AAR on survival compared to hematological, prostate, and urinary 
system cancers. In all other cancer types the confidence intervals overlapped suggesting that the 
impact of AAR on survival was similar.  
When the interaction between AAR and time of MDD diagnosis was included in the 
model, in digestive system cancers (except colorectal), among patients whose MDD was 
diagnosed before cancer, AAR was associated with higher risk of death (HR 2.10; 95% CI 1.09-
4.07), and in patients whose MDD was diagnosed after cancer, AAR was associated with a lower 
risk of death (HR 0.67; 95% CI 0.47-0.96). In lung cancer patients, AAR was associated with 
lower risk of death irrespective of time of MDD diagnosis and there was no statistically 
significant difference in the impacts of AAR on survival between patients whose MDD was 
diagnosed before cancer and patients whose MDD was diagnosed after cancer. In all other types 
of cancer, the impact of AAR on survival was not significant in patients whose MDD was 
diagnosed before cancer and AAR was associated with lower mortality risk in patients whose 
MDD was diagnosed after cancer. 
Table 4 
Adjusted impact* of AAR on the survival of cancer patients aged ≥ 65 years with MDD who 
survived at least a year following cancer diagnosis, by cancer type 
Cancer type HR 95% CI 
Breastabg 0.59 0.48 0.73 
Impact of AAR by time of MDD diagnosis†    
Before cancer diagnosis (AAR Yes vs No) 0.86 0.53 1.38 
After cancer diagnosis (AAR Yes vs No) 0.53 0.42 0.67 
Colon and Rectumabdeg 0.62 0.52 0.75 
Impact of AAR by time of MDD diagnosis†    
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Before cancer diagnosis (AAR Yes vs No) 0.81 0.53 1.22 
After cancer diagnosis (AAR Yes vs No) 0.58 0.47 0.71 
Digestive System, except Colon and Rectumch 0.89 0.66 1.20 
Impact of AAR by time of MDD diagnosis†    
Before cancer diagnosis (AAR Yes vs No) 2.10 1.09 4.07 
After cancer diagnosis (AAR Yes vs No) 0.67 0.47 0.96 
Female Genitalabg 0.49 0.35 0.67 
Impact of AAR by time of MDD diagnosis†    
Before cancer diagnosis (AAR Yes vs No) 1.14 0.59 2.22 
After cancer diagnosis (AAR Yes vs No) 0.35 0.23 0.51 
Hematologicalbcdeg 0.51 0.41 0.64 
Impact of AAR by time of MDD diagnosis†    
Before cancer diagnosis (AAR Yes vs No) 0.82 0.45 1.52 
After cancer diagnosis (AAR Yes vs No) 0.46 0.36 0.59 
Lung and Bronchusabdgh 0.57 0.46 0.71 
Impact of AAR by time of MDD diagnosis†    
Before cancer diagnosis (AAR Yes vs No) 0.65 0.44 0.96 
After cancer diagnosis (AAR Yes vs No) 0.53 0.41 0.69 
Otherbcg 0.55 0.46 0.66 
Impact of AAR by time of MDD diagnosis†    
Before cancer diagnosis (AAR Yes vs No) 0.72 0.50 1.06 
After cancer diagnosis (AAR Yes vs No) 0.50 0.40 0.62 
Prostatebg 0.53 0.44 0.63 
Impact of AAR by time of MDD diagnosis†    
Before cancer diagnosis (AAR Yes vs No) 0.77 0.50 1.17 
IMPACTS OF DEPRESSION AND ITS MANAGEMENT ON CANCER SURVIVAL 
95 
 
After cancer diagnosis (AAR Yes vs No) 0.48 0.39 0.59 
Urinary Systemabcg 0.43 0.33 0.55 
Impact of AAR by time of MDD diagnosis†    
Before cancer diagnosis (AAR Yes vs No) 0.66 0.36 1.23 
After cancer diagnosis (AAR Yes vs No) 0.39 0.29 0.52 
*Result of Cox proportional hazards regression stratified by cancer type and adjusted for time of 
MDD diagnosis, age, sex, ethnic concentration quintile, neighborhood income quintile, rural, 
cancer stage at diagnosis, and number of comorbidities other than MDD 
†Result of Cox proportional hazards regression, stratified by cancer type, with the interaction 
term between AAR and time of MDD diagnosis and the confounders (age, sex, ethnic 
concentration quintile, neighborhood income quintile, rural, cancer stage at diagnosis, and 
number of comorbidities other than MDD) included in the model 
ap<0.05 for time of MDD diagnosis   
bp<0.05 for age 
c p<.05 for sex 
dp<0.05 for ethnic concentration quintile 
ep<0.05 for neighborhood income quintile 
gp<0.05 for cancer stage 
hp<0.05 for number of comorbidities other than MDD 
Discussion 
This study evaluated whether adequate antidepressant refill defined as 180 days’ 
continuous refill of antidepressants, had an impact on the survival of older cancer patients with a 
hospital discharge diagnosis of major depressive disorder. MDD was diagnosed after cancer 
diagnosis for a majority of the sample (67.6%). It suggests that increased stress associated with 
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cancer diagnosis may lead to MDD. Alternatively, it may also be due to increased screening for 
MDD in patients after cancer diagnosis, since the clinical practice guidelines by Cancer Care 
Ontario recommends screening all cancer patients for depression (Li et al., 2016).  
A higher proportion of patients received AAR when their MDD was diagnosed before 
cancer compared to patients whose MDD was diagnosed MDD after cancer. However, this was 
mainly because in patients whose MDD was diagnosed after cancer, 22.9% died before 180 days 
of MDD diagnosis. In addition, after cancer diagnosis, antidepressants may not be prescribed to 
avoid disease progression (Christensen et al., 2016) and interactions with cancer drugs 
(Desmarais & Looper, 2009). It should also be noted that fewer patients diagnosed with later 
stages of cancer received AAR compared to patients diagnosed with earlier stages of cancer. In 
end-stage cancer patients, antidepressants may not be prescribed because they typically take four 
to six weeks to start showing benefits and have side effects that are particularly risky for such 
patients (Johnson, 2018). Instead, psychostimulants, and alternative treatments such as 
electroconvulsive therapy and herbal remedies are used for treating depression in end-stage 
cancer patients (Johnson, 2018). 
The results showed that those who received AAR had a lower risk of mortality when 
compared to those who did not receive AAR; however, the overall impact of AAR on cancer 
survival was significant only for patients diagnosed with MDD after cancer diagnosis. The 
results are in alignment with our assumption that proper management of MDD can lead to better 
health-related behaviours and as a result lead to better survival. In patients whose MDD was 
diagnosed before cancer, AAR might have resulted in a better control of MDD by the time of 
cancer diagnosis, and hence the impact of AAR on cancer survival might have been attenuated. 
Kaplan-Meier curves showed that patients whose MDD was diagnosed after cancer and did not 
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receive AAR had the lowest survival. Those patients might have had a poor survival prognosis 
due to cancer characteristics and that might have been the reason why they did not receive 
antidepressants in the first place.  
A recent study in Israel found that adherence to antidepressants is associated with 
reduced risk of mortality in patients (Shoval et al., 2019). The study calculated adherence by 
dividing the duration of purchase of antidepressants by duration of continuous prescription of 
antidepressants and considered those who scored below 20% as nonadherent. However, that 
study did not find any impact of antidepressant adherence on colon cancer survival (Shoval et al., 
2019) whereas our study found that colorectal cancer patients with MDD who received AAR had 
38% lower risk of death than those who received AAR. A similar study among patients with 
depression following myocardial infarction also showed that those who were treated with 
antidepressants had a lower risk of death compared to those who were not treated with 
antidepressants (Taylor et al., 2005). Their sample included patients with dysthymia, major 
depression, or minor depression (Taylor et al., 2005) whereas our study included patients with 
hospital diagnosis of MDD only, which given the severity of other presenting diagnoses, may be 
identified only when it is severe.  
An interesting finding was that for all types of cancers except digestive system other than 
colorectal and lung and bronchus, the impact of AAR on survival was not significant if MDD 
was diagnosed before cancer. Surprisingly, in patients with digestive system cancers other than 
colorectal, AAR was found to be associated with higher risk of death if MDD was diagnosed 
before cancer. Liver toxicity associated with antidepressant use in the older patients may be one 
of the reasons for the increased mortality associated with AAR in those patients (de Gage et al., 
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2018). AAR had a positive impact on the survival of all cancer types if the MDD was diagnosed 
after cancer diagnosis.  
Contrary to the studies that have shown increased mortality in breast cancer patients 
associated with antidepressant use (Busby et al., 2018; Wernli et al., 2011), our study showed 
that AAR had a protective effect on breast cancer survival, especially among patients with MDD 
diagnosed after cancer. The difference between our study and theirs is that they compared 
antidepressant users and non-antidepressant users in samples that included cancer patients with 
or without depression (Busby et al., 2018; Wernli et al., 2011) whereas our sample included 
cancer patients with MDD only and compared those who received AAR and those who did not 
receive AAR. In lung cancer patients, antidepressant use was found to be associated with better 
survival by a study in the USA (Zingone et al., 2017). However, that study did not ascertain 
whether the participants had depression or not and hence might have included lung cancer 
patients with or without depression. (Zingone et al., 2017).  
 Number of comorbidities other than MDD was not a significant predictor when 
considering all cancer types together. However, stratified analysis by cancer type found that 
patients with < 4 comorbidities had higher risk of death than patients with ≥ 4 comorbidities for 
digestive system except colorectal and lung and bronchus cancers. The positive association 
between number of comorbidities and survival may be due to reverse causality when those who 
lived longer developed more chronic conditions later in their life. It should be noted that lung 
and bronchus cancer patients had the second highest mortality (Table 1) and digestive system 
except colorectal had the lowest percentage of patients receiving AAR (Table 2). In older cancer 
patients it has been shown that in general comorbidities are associated with poorer survival 
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(Galvin et al., 2018), although some studies have failed to show any such impact (Antonio et al., 
2017).  
Diagnosing depression in older cancer patients is challenging because they may not 
acknowledge depressed mood and anhedonia, which are the main diagnostic symptoms for 
depression, and because the physical symptoms of cancer and old age such as fatigue, aches and 
pain, and sleep problems are similar to the physical symptoms exhibited by depressed patients 
(Weinberger et al., 2011). They are also less likely to be referred to specialized psychosocial care 
as evidenced by a study that showed that only 22% of patients aged ≥ 70 years were referred 
compared to 100% of patients aged ≤ 40 years (Ellis et al., 2009). The findings of this study 
provide evidence supporting the importance of proper diagnosis and management of depression 
in older cancer patients. 
Limitations 
This study assumed that since individuals ≥ 65 years are eligible for ODB drug coverage, 
details regarding their antidepressant use can be obtained from the ODB database. However, 
patients whose MDD was diagnosed before they turned 65 years old might not have been 
covered by ODB at the time of MDD diagnosis in which case their antidepressant use could not 
be identified from the ODB database. Therefore, there is a possibility that some of the patients 
who were identified as not having received AAR had received antidepressants either via private 
drug insurance or by paying from their own pockets, resulting in misclassification bias. This 
might have resulted in underestimation of the impact of AAR on survival. There is also the 
possibility that patients who did not receive AAR received non-medicinal management of MDD, 
which also would have attenuated the impact of AAR on survival. The results of sensitivity 
analysis showed that the analysis excluding patients who died within one year of MDD diagnosis 
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resulted in a lower estimate of risk of death (HR 0.87; 95% CI 0.79-0.96). This shows that our 
study might have reverse causality issues. 
We included only hospital-discharge diagnosis of MDD as the inclusion criteria, which 
excluded patients with outpatient diagnosis of MDD and milder forms of depression from 
participating in the study. Hence the results may not be generalizable for all older cancer patients 
with depression. Since the study was done in patients aged ≥ 65 years, the estimates may be 
different for younger cancer patients. 
Strengths 
Since this is a population-based study, which included all patients with cancer and MDD 
who were ≥ 65 years old and survived a year or more after cancer diagnosis in Ontario, it 
minimizes selection bias and facilitates decision-making better than studies on smaller samples. 
This study has a relatively long follow-up period (5.8 years in average), which allowed 
assessment of the impact of adequate antidepressant refill over a longer time period. Stratified 
results by cancer type showed the importance of AAR in improving the survival in all types of 
cancer patients and suggests that cancer patients with depression have worse survival outcomes 
in the absence of AAR.  
Conclusions 
Among older cancer patients with depression, adequate antidepressant refill had a 
protective effect on cancer survival, especially in patients whose depression was diagnosed after 
cancer diagnosis. To our knowledge, there have not been any studies in the past that examined 
the impact of antidepressant therapy on the survival of depressed cancer patients. Past studies 
have only compared cancer patients who used antidepressants and those who did not use 
antidepressants in samples including both depressed and nondepressed cancer patients. This 
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study demonstrates the scope of adequate antidepressant therapy in improving the survival of 
older cancer patients with depression. It shows that health care providers should give importance 
to depression and other mental health issues while creating a treatment plan for cancer patients, 
especially in the older age group. Extending insurance coverage for prescription drugs for 
younger (<65 years old) cancer patients may be beneficial for their adherence to antidepressants.  
Studies including patients with outpatient diagnosis of depression and/or of younger age 
group should be conducted to ascertain that the results of this study are generalizable for all 
cancer patients. Further studies are needed to examine the impact of other types of treatment for 
depression in cancer patients. The results also justify further research on access to mental health 
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ICES databases used for obtaining data for the study 
Database Description Variables  
Discharge Abstract 
Database (DAD) 
Information on hospitalizations in 
Ontario. Includes admissions, 
length of stay and discharges. 
Major depressive disorder 




Information on all Ontario 
residents diagnosed with cancer. 
Includes date of diagnosis, site of 
primary cancer and cancer deaths. 
Age at diagnosis, sex, primary 
cancer site, stage at diagnosis, 
time of death 
Ontario Health 
Insurance Plan (OHIP) 
claims database 
Information on claims paid for by 
OHIP. Includes physician visits, 
hospitalizations and associated 
diagnosis.  
Comorbidities including 
depression using the diagnostic 
codes, time of diagnosis 
Registered Persons 
Database (RPDB) 
Demographic information for all 
individuals who have ever had a 
valid Ontario health card number. 
Includes age, sex, neighbourhood 
income and residence.  
Neighbourhood income 




Information on outpatient visits to 
hospital and community-based 
ambulatory care. Includes day 
surgery, outpatient clinics, and 
emergency departments. 
Comorbidities including 
depression using the diagnostic 
codes, time of diagnosis 
Ontario Drug Benefit 
(ODB) claims 
database  
Information about drug claims by 
ODB beneficiaries such as drug 
Antidepressant use from DIN, 
time of refill, quantity 
dispensed 
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identification number, quantity 




Information regarding deprivation 
or marginalization based on 
residential instability, material 
deprivation, dependency, and 
ethnic concentration 
Ethnic concentration quintile 
 
  




List of antidepressants and their drug identification numbers 
Antidepressant generic 
name 
Drug identification number 
Amitriptyline 16306 
Amitriptyline HCL 37400, 335053, 335061, 335088, 654507, 654515, 2326043, 
2326051, 2326078, 2429861, 2429888, 2429896 
Bupropion HCL 2237824, 2237825, 2238441, 2260239, 2275074, 2275082, 
2275090, 2275104, 2285657, 2285665, 2313421, 2325373, 
2382075, 2382083, 2439654, 2439662 
Citalopram HBR 2239607, 2239608, 2246056, 2246057, 2246594, 2246595, 
2248010, 2248011, 2248050, 2248051, 2248170, 2248171, 
2251558, 2251566, 2252112, 2252120, 2275562, 2275570, 
2285622, 2285630, 2293218, 2293226, 2304686, 2304694, 
2306239, 2306247, 2313405, 2313413, 2322781, 2322803, 
2331950, 2331977, 2353660, 2353679, 2355256, 2355272, 
2355280, 2371898, 2371901, 2409011, 2409038, 2429705, 
2429713, 2430541, 2430568 
Clomipramine 2040751, 2040778, 2040786 
Clomipramine HCL 324019, 402591, 2139340, 2139359, 2139367, 2244816, 2244817, 
2244818 
Desipramine HCL 1946269, 1946277, 1948784, 1948792, 2216256, 2216264, 
2216272, 2223325, 2223333  
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Doxepin HCL 24333, 24341, 1913441, 1913468, 2049996, 2050005, 2050013, 
2050021, 2050048, 2050056, 2140098 
Duloxetine 2301482, 2301490, 2429446, 2429454, 2440423, 2440431 
Duloxetine HCL 2426633, 2426641, 2436647, 2436655, 2437082, 2437090, 
2438259, 2438267, 2438984, 2438992, 2439948, 2439956, 
2451913, 2451921 
Escitalopram 2454297, 2454300 
Escitalopram oxalate 2263238, 2263254, 2295016, 2295024, 2303949, 2303965, 
2309467, 2309475, 2313561, 2313588, 2318180, 2318202, 
2364077, 2364085, 2385481, 2385503, 2391449, 2391457, 
2397358, 2397374, 2407418, 2407434, 2423480, 2423502, 
2429780, 2429799, 2430118, 2430126, 2440296, 2440318 
Fluoxetine 2286076 
Fluoxetine HCL 636622, 2177587, 2216361, 2216590, 2237814, 2241374, 
2242178, 2243487, 2380579, 2385635, 2386402, 2392917, 
2405709 
Fluvoxamine 2240682, 2240683 
Fluvoxamine maleate 1919342, 1919369, 2218453, 2218461, 2231329, 2231330, 
2239953, 2239954, 2247054, 2247055, 2255529, 2255537 
Imipramine HCL 21504, 312797, 326852, 360201 
Maprotiline HCL 2158612, 2158620 
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Mirtazapine 2243910, 2248542, 2248543, 2248544, 2248762, 2250608, 
2256118, 2259354, 2267292, 2270927, 2274361, 2279894, 
2279908, 2279916, 2286629, 2299801, 2299828, 2299836, 
2352842, 2411709 
Moclobemide 2218410, 2232148, 2232150, 2239747, 2239748, 2240456, 
2243218 
Nefazodone HCL 2087383, 2237398, 2237399, 2237400 
Nortriptyline 2240789, 2240790 
Nortriptyline HCL 15229, 15237, 2177692, 2177706, 2223511, 2223538, 2231686, 
2231687, 2231781, 2231782 
Paroxetine HCL 1940473, 1940481, 2240908, 2240909, 2247751, 2247752, 
2247811, 2247812, 2248013, 2248014, 2248557, 2248558, 
2254751, 2262754, 2262762, 2269430, 2269449, 2368870, 
2368889. 2383284, 2411954, 2421380, 2421399, 2431785 
Phenelzine sulfate 476552 
Sertraline 2238280, 2238281, 2238282 
Sertraline HCL 1962779, 1962817, 2132702, 2240481, 2240484, 2240485, 
2242519, 2242520, 2242521, 2244838, 2244839, 2244840, 
2245159, 2245160, 2245161, 2245787, 2245788, 2245789, 
2273691, 2287390, 2287404, 2287412, 2353520, 2353539, 
2353547, 2357143, 2357151, 2357178, 2374552, 2374560, 
2374579, 2390906, 2390914, 2390922, 2399415, 2399423, 
2399431, 2402378, 2402394, 2402408, 2427788, 2427796 
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Tranylcypromine sulfate 1919598 
Trazodone HCL 579351, 579378, 702277, 1937227, 1937235, 2053187, 2053195, 
2053209, 2144263, 2144271, 2144298, 2147637, 2147645, 
2147653, 2231683, 2231684, 2277344, 2277352, 2277360, 
2348772, 2348780 
Trimipramine maleate 740799, 740802, 740810, 740829, 1940430, 2070987 
Tryptophan 2230202, 2237250 
Venlafaxine HCL 2103702, 2237279, 2237280, 2237282, 2273969, 2273977, 
2273985, 2275023, 2275031, 2275058, 2278545, 2278553, 
2278561, 2304317, 2304325, 2304333, 2310279, 2310287, 
2310295, 2310317, 2310325, 2310333, 2331683, 2331691, 
2331705, 2354721, 2360020, 2360039, 2360047, 2380072, 
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The purpose of this research was to study whether the presence of depression had an 
impact on the survival of cancer patients in the context of multimorbidity and to examine 
whether adequate antidepressant use had any effect on the survival of cancer patients with 
depression. Results showed that major depressive disorder recognized during a hospitalization is 
associated with higher risk of death in cancer patients and that number of comorbidities other 
than depression modifies the impact of depression on survival. Another key finding was that 180 
days’ continuous refill of antidepressants was associated with better survival in older cancer 
patients whose depression was diagnosed after a cancer diagnosis. 
6.1 Main Findings 
6.1.1 Depression is Associated with Poorer Cancer Survival 
The study results showed that cancer patients who had MDD had 58% higher risk of 
death than cancer patients without MDD when adjusted for all other covariates included in the 
study. This confirms our hypothesis that MDD has an impact on the survival of cancer patients. 
Other studies on the impact of depression on cancer survival have shown similar results (Chang 
et al., 2014; Prasad et al., 2014b; Prieto et al., 2005). A very recent population-based study in 
South Korea also found that pre-existing depression diagnosed within two years before cancer 
diagnosis was associated with 60% higher risk for mortality (A. Ko et al., 2019). In all types of 
cancer, depression increased the risk of death. Past studies on lung cancer (Vodermaier et al., 
2017) and breast cancer (Vodermaier et al., 2014) patients in Canada have found similar 
association between depression and cancer mortality.  
 Impact of MDD on survival was higher in patients with cancer types that have longer 
survival and lower in patients with cancer types that have shorter survival. In cancer’s with 
longer survival, MDD has a longer time to influence the patient’s lifestyle and quality of life 
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resulting in the higher impact of MDD on survival in patients with those types of cancers 
compared to patients with cancer types that have shorter survival.  
Interestingly, the impact of depression was higher in the younger (< 65 years) age group 
compared to the older age group. The reason might be because older cancer patients might have 
other severe comorbidities that affect their survival more than depression. Another explanation is 
better coordinated care in older patients due to the involvement of geriatricians, which decreases 
the impact of depression on survival. 
6.1.2 Number of Comorbidities Modify the Impact of Depression on Cancer Survival 
The impact of depression on cancer survival was higher in patients with fewer 
comorbidities. This might be because severity of other comorbidities had a greater impact on 
survival than depression in patients with more comorbidities. However, since the impact of 
MDD on survival was statistically significant at all levels of multimorbidity, it is important to 
identify and treat depression in all cancer patients to improve their survival. 
6.1.3 Adequate Antidepressant Refill is Associated with Better Survival in Cancer Patients 
with Depression 
Older (65 years and older) cancer patients with MDD diagnosed after cancer had higher 
chances of survival if they had 180 days’ continuous refill of antidepressants. The impact was 
statistically significant for all types of cancer. This result supports our hypothesis that adequate 
treatment of depression can result in improved survival of cancer patients with depression. AAR 
did not have an impact on the survival of older cancer patients whose MDD was diagnosed 
before cancer. This may be because MDD was well controlled before cancer diagnosis in those 
patients. Number of comorbidities did not have an impact on the survival of cancer patients with 
depression aged 65 years or more. 
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All covariates except rurality of residence were statistically significant predictors of 
overall mortality in cancer patients. This is similar to other studies conducted in Canada that 
found no rural/urban disparity in cancer survival (Canale et al., 2018; J. D. Kim et al., 2018). 
Those studies attribute the lack of rural/urban disparity to the publicly funded health care system 
in Canada, which ensures accessibility of health care to all residents (Canale et al., 2018; J. D. 
Kim et al., 2018). Income was a significant predictor of survival for the entire cohort, although 
for the older patients with depression, income was not statistically significant. Patients residing 
in neighborhoods with high-income had a better survival when compared to patients residing in 
low-income neighborhoods. This is similar to the findings of past studies in Canada (C. Boyd et 
al., 1999; McDonald et al., 2014). 
Similar to other studies (Ellison, 2016; Kinoshita et al., 2017; Radkiewicz et al., 2017), 
our results also showed that female cancer patients had better survival than males. Patients 
residing in locations with high concentration of recent immigrants had higher survival rates than 
patients from neighborhoods with lower concentration of recent immigrants. This corroborates 
the study by Cheung et al. (2017), which showed that immigrants have better cancer survival 
than Canadian-born patients. Prospective immigrants must undergo medical clearance for 
immigration, hence only relatively healthy individuals immigrate to Canada. Canada selects 
immigrants based on their education and skills, which also might influence their health 
outcomes.  
6.2 Limitations 
Misclassification bias related to administrative data is the main limitation of this study. 
Trustworthiness of administrative data depends on data completeness and accuracy of coding 
(Fortin et al., 2012). Patients may have outpatient diagnosis of MDD, which was not identified 
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by this study, leading to an underestimation of MDD prevalence. Hospitalized cancer patients 
have a high risk of death (Numico et al. 2015) and hence diagnosis of MDD in hospitalized 
patients implies that MDD is diagnosed in patients with higher likelihood of death. Hence, this 
study might have differential misclassification bias where patients who are likely to have the 
outcome are more likely to have been identified as exposed, resulting in overestimation of the 
impact of MDD on survival and reverse causality. Depression is recognized as a diagnosis during 
hospitalizations only in patients with severe depression, which also could have led to 
overestimation of the impact of MDD on survival.  
Although depression is managed with psychotherapy in addition to antidepressants, 
information regarding psychotherapy is not available from OHIP databases since it is not 
covered by OHIP. Hence, we do not know whether the study participants received 
psychotherapy. Since patients included in the non-exposed group (who did not receive AAR) in 
pat 2 of the study could have had their depression managed by non-medicinal methods, the 
resulting misclassification bias would have resulted in an underestimation of the impact of AAR 
on survival. The significantly lower HR estimates when the patients who died within a year of 
MDD diagnosis were excluded from the analysis signifies that there could be potential reverse 
causality bias in the second part of the study. 
Patients may have other chronic diseases which were not included in this study and hence 
the number of comorbidities might have been underestimated. Severity of comorbidities may 
impact survival more than number of comorbidities. Not considering severity of comorbidities 
when calculating level of multimorbidity is another limitation of this study. Health behaviours 
such as smoking, physical exercise, and alcohol use are important factors that influence survival; 
however, due to limitations of data availability they were not included as confounders. 




The first part of the study included all adults in Ontario who were diagnosed with cancer 
during the index period and hence analysed a large population-based data. The second part also 
included all Ontario residents diagnosed with cancer at age ≥ 65 years and had a hospital 
diagnosis of MDD. Population-based estimates can inform decision-making better than studies 
on small samples. The follow-up period is long, 7.5 years for the first part including all adult 
cancer patients and 5.8 years for the second part including cancer patients aged ≥ 65 years with a 
hospital diagnosis of MDD, which allowed the assessment of longer-term survival among cancer 
patients. Since provincial-level data were analysed, selection bias was minimum. Multiple types 
of cancer were included in this study and stratified analyses showed the impact of depression and 
adequate antidepressant refill on the survival of different types of cancer.  
6.4 Epidemiological Implications: Internal Validity/External Validity 
Since we identified depression only in hospitalized patients having a diagnosis of major 
depression, we most certainly underestimated the prevalence of depression. The specificity of the 
study in identifying MDD was high since the patients diagnosed with MDD during 
hospitalizations would be severely depressed and there is low likelihood of patients without 
MDD being identified as depressed. However, since some patients classified as not having MDD 
might have had MDD diagnosed in outpatient settings, the study might have been less sensitive 
in identifying MDD. As a result, the estimated impact of MDD might have been less than what 
would have been if all cases of MDD were identified. The prevalence of MDD estimated by this 
study is 2%, which is much lower than the annual prevalence of major depression in Canada, 5% 
(Patten et al., 2016).  
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For the second part of the study, we might have included some patients who received 
adequate antidepressant refill in the group that did not receive adequate antidepressant refill if 
their MDD was diagnosed before they turned 65 years old and became eligible for ODB. If all 
patients who received AAR were identified correctly, the HR estimates might be higher than 
what we have calculated.  
Since this is a population-based study, with minimal selection bias, and the analyses 
adjusts for the main confounders, the internal validity is high. External validity is also high and 
the results may be applicable for the rest of Canada and high-income countries with a similar 
population. However, the contextual factors mentioned in the Andersen model (Andersen, 1995) 
should be considered when applying the study results. Social and cultural characteristics and 
health beliefs can vary in different populations and hence the estimates may differ for specific 
communities. Access to mental health care may differ in countries where there is high stigma 
around mental health. Treatment approaches for depression may also be influenced by the 
characteristics of the health systems and society. In Canada, the impact of depression on survival 
can be higher among Indigenous people than our population-level estimates due to the mediating 
factors such as poor access to care (Lavoie et al., 2016), low quality of care, and racial 
stereotyping (Browne & Fiske, 2001). A high percentage of indigenous people live on reserves 
(Statistics Canada, 2018b), which also can be an obstacle to accessing care and impact their 
survival. 
We compared patients with a hospital discharge diagnosis of MDD and those without a 
hospital discharge diagnosis of MDD. Therefore, the results may not be sufficiently relevant for 
those with milder forms of depression. For the second part studying the impact of 
antidepressants, only patients who were ≥ 65 years old at the time of cancer diagnosis and had a 
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hospital diagnosis of MDD were included. Hence, the results are applicable for that age group 
only. Validity of the results of stratified analysis by type of cancer in part 2 is limited because of 
smaller number of patients in each category (For example, n=240 for digestive system cancers 
except colorectal, among whom only 32 were alive). 
  











Chapter 7: Conclusion: Summary/Implications/Future directions 
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The results of this population-based study in Ontario showed that depression is associated 
with shorter survival in cancer patients and the impact of depression on survival changes 
according to number of other chronic diseases in a cancer patient. The study also showed that, 
among older cancer patients with depression, adequate antidepressant refill is associated with 
decreased mortality, specifically in patients whose MDD was diagnosed after cancer. The results 
encourage health care providers to identify depression in cancer patients, provide adequate 
treatment/prescribe appropriate medication, and to promote adherence to depression treatment to 
improve cancer survival. 
In all types of cancer, MDD was associated with shorter survival and in all types of 
cancer patients with MDD, AAR was associated with better survival. Although the impact of 
MDD on survival was smaller for cancers with poorer prognosis, the finding that there still was 
an impact stresses that it is important to identify and treat depression in all types of cancer. 
Appropriate treatment of depression can improve the quality of life of cancer patients with 
depression (Fisch et al., 2003), which is crucial even if the duration of survival is less.  
In Ontario, the Ontario Health Insurance Plan (OHIP) provides coverage for 
hospitalizations and doctors’ visits for all residents, but drugs prescribed in non-hospital settings 
are not covered (Ontario, 2020b). OHIP+ provides prescription drug coverage for residents under 
25 years of age if they do not have private insurance (Ontario, 2017) and Ontario Drug Benefits 
plan provides prescription coverage for adults aged 65 or more. Adults between 25 and 65 years 
of age are not covered for prescription drugs by the provincial health insurance programs 
(Ontario, 2020b). Extending drug coverage to all age groups may improve access and adherence 
to antidepressants, since individuals without drug insurance may not adhere to medications due 
to cost-related issues (Law et al., 2012). 
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This study showed that depression had an impact on the survival of patients with cancer, 
which is a chronic disease. Mental health conditions may go undiagnosed in patients with 
chronic conditions. The results of this study may be applicable to patients with or without other 
chronic diseases. Therefore, identifying depression and other mental health issues in individuals 
and providing adequate treatment is important for the health of the population. Public health 
measures for improving access to mental health care should be promoted. 
Future studies should identify the impact of minor depression and depression diagnosed 
in outpatient as well as inpatient settings on cancer survival. Impact of antidepressants in 
younger cancer patients with depression should also be studied. Identifying the factors associated 
with adequate antidepressant refill can assist in developing programs for improving treatment 
compliance in cancer patients. Studies on non-medicinal management of depression and their 
impacts on outcomes in cancer patients will help to determine the best methods in managing 
depression in cancer patients. Mental illnesses and their influence on other outcomes such as 
quality of life and quality-adjusted life years may also be studied. The results also justify further 
research on access to mental health treatment for cancer patients in Canada. Research 
investigating the effect of depression and other mental heath disorders on the survival and other 
outcomes in patients with other chronic diseases should also be encouraged. 
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